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ABSTRACT 
 
The hepatitis C virus genome encodes a 63 amino acid protein, p7. The exact role of 
p7 is unknown; in this study we observed that mutations in transmembrane domain-1 and 
-2 (TM1 and TM2), and the cytoplasmic loop of p7 decreased infectious virus production. 
Analysis of p7 at different stages of virus assembly revealed that p7 functions at a stage 
prior to generation of infectious particles. Confocal microscopy analyses indicated that p7 
did not affect recruitment of core protein to lipid droplets. Additionally, mutation of p7 
did not affect formation of core multi-order structures. Finally, mutations at the 
cytoplasmic loop significantly reduced intracellular E2 glycoprotein levels. Forced 
evolution analysis of p7 mutations resulted in the occurrence of a N765D mutation that 
was important for secretion of virus particles into the culture supernatants. The results of 
this study provide strong evidence that p7 functions to protect HCV glycoproteins from 
premature degradation and we suggest that p7 supports the virus assembly process. 
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CHAPTER 1: INTRODUCTION 
 
1.1 HCV overview 
Hepatitis C virus (HCV) is the major cause of several severe liver diseases including 
chronic hepatitis, liver fibrosis, cirrhosis, and hepatocellular carcinoma; often resulting 
from complications of persistent HCV infection. These disorders can lead to liver 
transplantation to treat liver failure in infected individuals [1]. The estimated rate of HCV 
infection around the world is 2.6-3.1% representing 122-185 million symptomatically 
infected individuals [2]. Unfortunately, there is no prophylactic vaccine and the current 
combinations of pegylated interferon-α (Peg-IFNα) and ribavirin are expensive and 
associated with severe side effects [3,4]. This combination has been reported to be only 
successful for approximately 50% of individuals infected with HCV genotype-1 (G1). 
Treatment success is defined as the achievement of undetectable HCV RNA by currently 
available clinical laboratory assays for at least 6 months after treatment and termed a 
sustained virological response (SVR). Interestingly, 80% of patients infected with G2 or 
G3 and 60% of patients infected with G4 achieve such a clinically defined SVR [4,5]. In 
2011, two direct-acting antiviral compounds (DAAs) targeted to the virally encoded 
protease (NS3-4A) became available as part of a new triple therapy approach in 
combination with Peg-IFNα and ribavirin. This breakthrough led to improvement of the 
SVR rate from approximately 50% to 70% for G1-infected patients [6,7]. However, this 
new strategy was limited to certain genotypes (G1 and G2) and associated with viral 
resistance mutations, and increased drug toxicity and side effects [8]. Therefore, efforts 
 
 
3 
 
are ongoing to develop improved treatment options. A better understanding of basic HCV 
virology will doubtlessly impact the identification of novel therapeutic targets.    
1.2 HCV discovery and classification 
Early in the 1970s, an unknown etiological agent that was neither hepatitis A virus   
(HAV) nor hepatitis B virus (HBV) (non-A non-B) was considered to be the major cause 
of parental acquired and post-transfusion hepatitis [9]. In 1989, the Chiron group 
succeeded in partial-genome cloning and development of an antibody detection system 
for diagnosis of infection with this unknown virus, which was then called HCV [10,11]. 
Consequently, the full length HCV genome was characterized  and found to be a positive-
sense single-stranded RNA of approximately 9.6 kb in length [12-14]. The genome 
organization, and HCV viral precursor proteins, as well as the morphological features of 
HCV particles taken from human serum and liver tissue were shown to be congruent with 
that of flaviviruses and pestiviruses in the Flaviviridae family [15-18]. However, because 
of the low sequence homology of HCV with that of flaviviruses and pestiviruses, HCV 
was classified in a distinct genus termed hepacivirus [19]. Subsequently, the genus 
included the enigmatic GB-virus B and the newly-identified non-primate, rodent and bat 
hepatitis viruses (NPHV, RHV and BHV) [20-22]. 
There are at least 7 genotypes of HCV (G1-G7) that differ by approximately 30% in 
their nucleotide sequence [23]. These genotypes are further classified into subtypes (a, b, 
c, d, etc). The variations are attributed to the high mutation rate of HCVs error-prone 
RNA polymerase and diverge in worldwide distribution, transmission, and disease 
progression [24]. As another repercussion of the error-prone polymerase, HCV circulates 
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as a diverse population of closely related variants in infected individuals, referred to as a 
quasispecies [25]. 
1.3 HCV genome organization 
Since the elucidation of the full length HCV genome, it became understood that the 
positive-sense RNA genome encodes a long polyprotein precursor encoded by an open 
reading frame (ORF) of approximately 3010 amino acids (aa) with minor genotypic 
variation (3008-3037 aa) [26]. Processing of the polypeptide chain occurs in a co- and 
post-translational manner, with cleavages catalyzed by cellular and viral proteases to 
generate the mature forms of each individual protein (Figure 1.1) [27-29]. The 1st third of 
the genome encodes the viral proteins core, and envelope glycoproteins 1 and 2 (E1 and 
E2), which are the structural components of the virion [26]. Downstream of these proteins 
is the viral protein, p7, which is dispensable for RNA replication, but its role in the virion 
assembly process is becoming of further interest to the research community [30,31] and 
the subject of this thesis. The remaining two thirds of the genome encode the non-
structural proteins (NS) in the order: NS2, NS3, NS4A, NS4B, NS5A and NS5B. The 
non-structural proteins act to catalyze polypeptide cleavages, form replication complexes 
and perform crucial roles in the assembly process [26,32]. The HCV ORF is flanked by 5′ 
and 3′-untranslated regions (5′-UTR and 3′-UTR). The 5′-UTR (~341 nucleotides) is 
highly conserved due to its possession of an internal ribosomal entry site (IRES) [33] that 
mediates genome translation [34]. The 3′-UTR (~139 nucleotides) most likely functions 
during initiation of genome replication [13,35]. 
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Figure 1.1 HCV genome structure and its translation and processing. The HCV 
genome (top panel) contains an approximately 9.6 kb open reading frame (ORF) flanked 
by 5′- and 3′-untranslated regions (UTRs). Translation is initiated at the IRES sequence 
within the 5′- TR to generate a 3000 amino acids polypeptide chain comprised of 
unprocessed structural proteins core and envelope glycoproteins 1 and 2 (blue boxes; 
middle panel), as well as the non-structural proteins 2-5B (red boxes). The viral protein 
p7 is neither a structural nor non-structural protein (green box). The polypeptide 
undergoes co- and post-translational processing in the endoplasmic reticulum (ER) to 
generate the mature forms of the viral proteins (enzymatic digestion sites are indicated by 
symbols (bottom panel) as defined in the insert). 
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1.4 HCV virion structure and physical properties 
Based on the better characterized virion structural arrangement of the related 
flaviviruses, it has been suggested that HCV particles are enveloped with a host-derived 
lipid membrane bi-layer, and display surface viral glycoproteins E1 and E2 in complex 
(Figure 1.2a). Beneath the envelope resides the viral nucleocapsid that consists of an 
oligomerized version of core and encases a single copy of the viral RNA genome [36]. 
Electron microscopic visualization of HCV particles derived from patient serum and liver 
tissue showed a spherical shape particle of 50 to 70 nm in diameter [15-17]. 
The nucleocapsid is 50 nm in diameter and icosahedral in structure [16]. The buoyant 
density of HCV particles derived from patient serum is low and heterogeneous (1.04-1.13 
g/ml), which is unusual for enveloped RNA viruses [37]. Serum-derived HCV particles 
were immunoprecipitated by using antibodies to apolipoprotein-E (Apo-E) and 
apolipoprotein-B (Apo-B), interacting with Apo-A1, ApoB-48, Apo-B100, and Apo-E, 
suggesting association of circulating HCV particles with serum low density lipoproteins 
(LDL) and very low density lipoprotein (VLDL) [38-40]. These features along with 
immunoglobulin bound circulating particles might explain such unusual heterogeneous 
density distribution (see section 1.7.5). 
Conversely, cell culture-derived (HCVcc) particle densities range between 1.0 and 
1.18 g/ml and interact with Apo-E, but Apo-B interaction was varied [41-45]. The lipid 
profile of HCVcc particles revealed a similar lipid and cholesterol composition to serum-
derived particles. Despite this similarity, the apolipoprotein class in cell culture could not 
be consistently defined [42]. The discrepancies between serum and HCVcc- 
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Figure 1.2 HCV virion structure. (a) Model of hepatitis C virus particle. (b) 
Model for the lipoviral particle (VLP) in which the virion is associated with LDL or 
VLDL. 
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derived particles can be attributed to a defect in the Huh7 cell lines ability to secrete Apo-
B containing VLDL particles [46]. 
The association of HCV particles with serum lipoproteins suggests that HCV particle 
synthesis relies on cellular lipoprotein formation and HCV virions form a hybrid lipoviral 
particle (LVP) (Figure 1.2b). This hybrid formation might protect circulating particles 
from antibody neutralization or lysis in an extra-hepatic environment, as well as facilitate 
virus entry into hepatocytes [47]. However, the exact mechanism of association is still 
unclear. Further details on the correlation between HCV formation and cellular lipid 
synthesis are discussed subsequently in this thesis.  
1.5 HCV proteins 
Core protein is the building block of the viral nucleocapsid and can be divided into 
two domains: D1 and D2. D1, formed by the N-terminal two-thirds of core, is highly 
hydrophobic and contains multiple positively charged amino acids suggested to be 
important for viral RNA binding and homo-oligomerization of core [48,49]. D2 forms the 
C-terminal third of core protein and is important for association with lipid droplets (LD); 
the primary site of HCV nucleocapsid assembly. This association is required for virus 
production in cell culture [48,50]. Expression of core protein alone in transgenic mice 
leads to steatosis and development of hepatocellular carcinoma (HCC) [51,52]. It has 
been suggested that core protein upregulates fatty acid biosynthesis in Huh7 cells and 
interacts with Apo-AII. This research leads to the intriguing indication that core plays a 
major role in pathogenesis and development of liver steatosis and HCC via deposition of 
triglycerides in the liver [50] (HCV proteins with the known and putative up to date 
functions are listed in Table 1.1). 
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Table 1.1 HCV proteins 
 
Viral proteins listed with their approximate nucleotide (nt) and amino acid (aa) length 
shown in the 1st and 2nd columns, respectively. The molecular mass in kilo-Dalton (kDa) 
as observed in SDS-PAGE analysis is listed in the 3rd column, and up to date known and 
putative function are listed in the last column. 
 
 
 
 
Viral 
protein 
Approximate 
nt/aa length 
Molecular mass 
(kDa) Function 
Core 573/191 
(mature form 
is 173-179 aa) 
21 RNA binding, nucleocapsid 
formation, upregulation of lipid 
metabolism 
E1 576/192 33 Envelope formation, mediation of 
viral entry 
E2 1089/363 70 Envelope formation, mediation of 
viral entry and antibody escape 
p7 189/63 7 Ion channel, virus assembly 
NS2 651/217 21 Virus assembly 
NS3 1893/631 69 NS viral protein processing, 
inhibition of innate immunity and 
helicase activity 
NS4A 162/54 6 NS3 cofactor 
NS4B 783/261 27 Membranous web formation 
NS5A 1341/447 56-58 Genome replication and assembly 
NS5B 1773/591 68 Viral polymerase 
 
 
10 
 
Envelope glycoproteins E1 and E2 are structural components of the HCV particles 
that form non-covalent complexes and are required for virus entry via receptor binding. 
E1 and E2 contain N-terminal ectodomains and C-terminal hydrophobic membrane 
anchors [53,54]. A critical post-translation N-linked glycosylation and disulfide bond 
formation is required for heterodimer complex formation and host receptor binding 
[53,54]. 
E2 binds to the host tetraspanin receptor protein CD81 and scavenger receptor-B1 
(SR-B1) found on the surface of hepatocytes and facilitates the entry process [55,56]. 
Furthermore, E2 was shown to possess hypervariable regions termed HVR-1 and HVR2 
that continuously change in patients with HCV infection. The HVRs are significant in 
viral escape from neutralizing antibodies [57]. 
p7 is an integral membrane protein that has been shown to form ion channel activity 
and is suggested to be important for virus assembly (reviewed in [58]). p7 is the major 
protein of interest in this work, and as such will be described in details following the 
general introduction (section 1.10). 
NS2 is a transmembrane autoprotease that is composed of two domains: an N-terminal 
membrane anchor and a C-terminal cysteine protease, which cleaves itself from the 
adjacent NS3 protein after translation [28,59]. NS2 is required for HCV infectivity in vivo 
and in HCV cell culture system (HCVcc), but is dispensable for viral RNA replication 
[60,61]. It has been shown that NS2 homodimerizes and can interact with other viral 
proteins. These interactions have led to the suggestion that NS2 has a major role in the 
HCV assembly process [62-66]. 
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NS3 is composed of an N-terminal serine protease and a C-terminal RNA helicase 
[67,68]. NS4A protein functions as a cofactor to optimize NS3 protease activity and ER 
targeting. NS4A contributes to proper folding of NS3 and stabilizes the protease to 
prevent its degradation [69,70]. NS3 with its cofactor, NS3-4A, is responsible for 
polyprotein processing of the non-structural proteins either independently, or 
autocatalytically in tandem with NS2 [71]. Additionally, NS3-4A induces proteolysis of 
Mitochondrial antiviral-signaling protein (MAVS) and Toll/interleukin-1 receptor-
domain-containing adapter-inducing- interferon-β (TRIF) adaptor proteins that leads to 
inhibition of the retinoic acid inducible gene-1 (RIG-I) pathway and Toll-like receptor-3 
signaling, respectively, thereby inhibiting an innate immune response by blocking IFN 
production [72-75]. The C-terminal helicase of NS3 binds RNA with a high affinity and 
unwinds RNA helices in an ATP-dependent manner [76,77]. The role of RNA unwinding 
in the life cycle has yet to be fully elucidated. Multiple theories have been developed: (i) 
it may be important for RNA replication through unwinding of secondary structures or 
stable stem-loops at the termini of the viral RNA genome [78]; (ii) it could be important 
for HCV assembly and RNA genome transfer and packaging into the newly-formed 
nucleocapsid [32,79]. 
NS4B is an ER-associated protein composed of two amphipathic helices at the N-
terminal domain, 4 transmembrane (TM) segments at the central domain, and a 
palmitoylated C-terminal domain containing two α-helices [80]. NS4B induces ER 
membrane alteration forming a ‘membranous web’ during infection. This membrane 
manipulation suggests that NS4B is crucial for the establishment of replication complexes 
[81]. Intriguingly, NS4B has RNA binding capability and ATPase/GTPase activity, but 
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the requirement for such activities within the HCV life cycle remains controversial [82-
84]. 
NS5A is a multifunctional protein involved in HCV replication and assembly. NS5A 
is a zinc-binding metalloproteinase protein and has no TM domains. The protein can be 
divided into 3 domains. The N-terminal domain (D1) of NS5A has a conserved RNA 
binding groove and is important for membrane attachment and LD targeting [85-87]. The 
second domain (D2) is less conserved and important for viral genome replication [87]. D2 
of NS5A has been shown to inhibit interferon-induced double stranded RNA activated 
protein kinase R (PKR), and inhibit IFN-gamma production [88,89]. In other studies, the 
D2 domain of NS5A was shown to interact with the host protein cyclophilin A to support 
viral genome replication [90-92]. Cyclosporin inhibits HCV replication  by blocking the 
interaction between NS5A and cyclophilin A [90]. The C-terminal domain (D3) is also 
less conserved and required for virus production, but dispensable for RNA replication 
[93,94]. NS5A has been detected in basal and hyper-phosphorylated forms. It has been 
suggested that NS5A is required for delivery of newly synthesized RNA genomes to the 
site of nucleocapsid formation at the surface of LDs, and that phosphorylation status 
maintains the balance between RNA replication and assembly [94-96]. This notion was 
supported by the finding that mutations reducing the levels of hyper-phosphorylated form 
led to a significant enhancement in RNA replication [97,98]. In transgenic mice, NS5A 
was shown to inhibit innate and adaptive immune responses [99]. Altogether, these 
studies highlight the importance of this protein at multiple stages of viral morphogenesis 
and justify NS5A as a current target for development of antiviral therapy. The drug 
daclatavir is one typical example of NS5A inhibitors that showed rapid decline of HCV 
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RNA in both cell culture and serum of infected patients, thereby providing a promising 
future treatment for HCV infection [100].    
NS5B is the well-characterized viral RNA-dependent RNA-polymerase that mediates 
RNA genome amplification. NS5B is anchored to the ER membrane via its first 21 C-
terminal amino acids [101]. The crystal structure of the protein revealed typical finger, 
palm and thumb subdomains. The active site possesses the GDD amino acids motif where 
the finger and thumb subdomains guide the RNA to the active site through tunnel 
formation [102,103]. NS5B generates a high error-rate during replication due to its lack 
of a proofreading mechanism (reviewed in [104]). 
1.6 The untranslated regions of HCV 
The ORF of HCV is flanked by 5′- and 3′-UTRs that contain essential elements for 
HCV translation and replication. The 5′-UTR possesses the IRES sequence that initiates 
cap-independent translation of the viral genome via binding to host cell ribosomes. The 
IRES contains 4 RNA stem-loops termed I to IV of which domain IIId constitutes the 
binding site for the 40S subunit of host ribosomes [34]. The host noncoding RNA element 
termed microRNA-122 (miR-122) was shown to interact with the 5′-UTR and modulate 
HCV translation [105]. The abundance of miR-122 was directly proportional to HCV 
translation efficiency, highlighting the importance of miR-122 as a host factor target for 
HCV therapy [106]. 
The 3′-UTR of HCV initiates positive-strand synthesis and stimulates IRES-dependent 
translation of the viral genome [107,108]. It forms three different domains including a 
short variable region, a poly U/UC domain, and a highly conserved 3′-X tail [109]. The 
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poly U/UC was found to be part of the HCV-associated pathogen associated molecular 
pattern (PAMP) recognized by the innate immunity receptor RIG-I [110]. 
1.7 HCV life cycle 
1.7.1 HCV entry 
Multiple receptors have been reported to be involved in HCV entry into hepatocyte- 
derived cell lines such as Huh-7.5 (Figure 1.3). Initial low-affinity attachment is mediated 
by LDL and glycosaminoglycan (GAG) receptors found on the surface of host liver cells 
[111,112]. Because HCV circulates in the blood as LVPs, both receptors are thought to 
interact with the virion-associated ApoE. This speculation has been supported by the 
finding that antibody blocking and LDL receptor knockdown reduced HCVcc infection 
[113]. Subsequently, CD81 and SRB1 receptors mediate tight binding of HCV to infected 
cells [114,115]. CD81 directly binds to the HCV E2 protein and primes HCV E2 for low 
pH-dependent fusion [116]. Antibodies against CD81 and SRB1 were shown to inhibit 
HCV infection after attachment, substantiating the involvement of CD81 and SRB1 after 
initial binding of HCV to host cells [117-119]. The tight junction proteins OCLN and 
CLDN1 are also important for HCV entry at a post-binding step [120,121]. OLCN and 
CLDN1 do not bind directly to E2, but CLDN1 was shown to be important for virus entry 
through its interaction with CD81 [122]. Engineered mice expressing human OCLN and 
CD81 were found to be permissive to HCV infection, but the exact contribution of OCLN 
in virus entry is still under investigation [123,124]. Auxiliary receptor including 
epidermal growth factor receptor (EGFR) and ephrin receptor type A2 have been 
implicated in the stabilization of the CD81-CLDN1 interaction [125].  
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The internalization of HCV occurs through clathrin-mediated endocytosis; a process 
leading to association of the virion with endosomal vesicles inside the host cell [126]. In 
summary, HCV entry seems to be a sequential process mediated by stepwise receptor 
engagement. This cascade of receptor interactions and conformational changes leads to 
virion internalization. Considering this, HCV liver tropism is likely determined by the 
collective association of these receptors on the hepatocyte (reviewed in [32,127]).    
1.7.2 HCV fusion 
Fusion is considered one of the least understood steps in the life cycle of HCV. The 
fusion process in related viruses, such as tick borne encephalitis virus, is well known and 
the fusion peptide within the E protein has been identified [128]. In pestiviruses, the 
fusion peptide resides in the E1 protein [129,130]. Therefore, some have proposed that 
HCV may possess an analogous mechanism of fusion. The viral envelope fusion with the 
endosomal membrane requires low pH-endosomes to induce viral genome release into the 
cytoplasm [131,132]. Multiple reports have suggested that a class-II fusion protein resides 
within the HCV E1 protein [133,134]. Others have argued that the fusion activity resides 
in E2 protein [135]. Therefore, the mechanisms of fusion and uncoating of internalized 
HCV particles remain unsolved and need to be fully characterized.  
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Figure 1.3 HCV life cycle. HCV entry is mediated by a sequential binding to multiple 
receptors that leads to internalization of the virus by clathrin-mediated endocytosis (1). 
Then, pH dependent fusion and release of the HCV genome take place after dissociation 
of the HCV-associated clathrin coated vesicles (2). Subsequently, the IRES mediates 
ORF translation and formation of a polyprotein precursor that is then processed to 
generate individual mature forms of the viral proteins (3). Viral RNA replication occurs 
within a modified ER membrane termed the membranous web (4). Then, viral assembly 
takes place at ER-associated LDs (5) and mature virus is released from the infected cell 
through a cellular secretory pathway (6). 
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1.7.3 HCV genome translation and post-translation modification 
Once the HCV genome is freed from the capsid within the cytoplasm of infected cells, 
viral translation initiation takes place at the ER surface by formation of the translation 
complex in a multistep process including: (i) formation of a binary complex between the 
HCV IRES and the 40S ribosomal subunit; (ii) assembly of a 48S complex at the AUG 
initiation codon with the eukaryotic translation initiation factor 3 (eIF3), GTP and Met- 
tRNAmet, and (iii) hydrolysis of the GTP and joining of the 60S subunit forming the 
IRES-80S complex [109]. 
Translation of the HCV ORF yields a polyprotein precursor that is co- and post-
translationally processed to liberate the mature form of each individual viral protein 
(Figure 1.1 and Figure 1.3). The mature structural proteins are further processed by host-
encoded signal protease cleavage [27,136,137]. Additional processing at the C-terminal 
end of core protein is needed to generate the mature form of this protein and is mediated 
by host signal peptide peptidase cleavage [138]. The cleavage efficiency at the E2-p7 and 
p7-NS2 junctions is poor, suggesting the existence of functional precursor sequences 
[137,139].  
The NS2 protein autocatalytically cleaves itself at the junction between NS2 and NS3 
by the activity of its cysteine protease domain [140]. The second virally-encoded protease 
NS3, along with its co-factor NS4A, cleaves the remaining non-structural proteins 
[141,142]. The NS3-4A serine protease cleaves at the NS3-NS4A site in a cis-acting 
manner, whereas the cleavages at the downstream sites are carried out in a trans-acting 
manner [143-145]. More importantly, the cysteine residues at the cleavage sites are 
conserved in all trans-cleavage sites, as mutations therein impaired cleavage and 
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processing of NS proteins [146]. In summation, HCV precursor protein processing by 
host and viral encoded proteases yields 10 different HCV proteins in the following order 
NH2-C-E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B-COOH. 
1.7.4 HCV genome replication 
The aim of viral genome replication is to amplify genetic material to be packaged in 
the newly formed virions during the morphogenesis cycle. All positive-strand RNA 
viruses perform RNA replication in a distinctive altered membrane structure that can be 
derived from ER, Golgi, mitochondria or lysosome (reviewed in [147]). The altered 
membrane structure formed in HCV-infected cells was found in the ER and was named 
the membranous web, which is most likely induced by the viral protein NS4B [81,148]. 
The membranous web forms distinct factories composed of viral proteins, altered cellular 
proteins and replicating RNA that altogether form the replication complex [148]. 
The RNA-dependent RNA polymerase enzyme (NS5B) uses the positive strand as a 
template to synthesize a negative strand intermediate. Subsequently, the enzyme uses the 
negative strand as a template to synthesize positive strands [102]. NS3 possesses a 
helicase domain that could be important for unwinding secondary RNA structure or 
displacement of RNA-binding proteins in support of genome replication [149]. 
Additionally, NS5A D1 and D2 were shown to be essential for RNA replication [87,150]. 
However, the exact contributions of NS3 and NS5A to RNA replication still need to be 
conclusively identified. It remains unclear how NS5B activity is regulated during RNA 
replication, but multiple hypotheses have been proposed including: (i) NS5A binds NS5B 
to modulate its activity [102]; (ii) the flexible beta-hairpin loop at the thumb domain was 
shown to regulate the RNA binding and initiation of RNA synthesis [151], and (iii) the 
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regulation of NS5B activity can be mediated by multiple host intracellular factors, such as 
sphingomyelin, cyclophilin A and B (CyPA and CyPB), and the NS5A binding partner, 
protein kinase C-related kinase 2 (PRK2), and human vesicle-associated membrane 
protein-associated protein A (hVAP-A) [152-156]. However, the exact mechanism of 
regulation and the contributions of the above-mentioned host factors in HCV infection are 
still not clear. 
1.7.5 HCV assembly process and release 
After viral protein maturation and RNA replication, an organized assembly process 
brings together nascent virion components. The following section describes a putative 
stepwise process of virus assembly that is also shown in Figure 1.4. 
1.7.5.1 Trafficking of core to LD 
The viral assembly process is assumed to begin with accumulation of core protein at 
the surface of cellular organelles termed lipid droplets (LD) (Figure 1.4) [157].   
Cholesterol esters and neutral lipids are stored in the cytosolic LD (cLD) that are 
surrounded by a phospholipid monolayer derived from the outer leaflet of the ER [158]. 
The aim of core trafficking to cLD is not clear but it has been hypothesized that this 
process sequesters the core protein until it’s needed for virus assembly and that the 
surface of cLD can subsequently serve as a platform for nucleocapsid assembly [47].  The 
D2 domain of the core protein has implicated importance in accumulation of core around 
LD because mutations in D2 inhibit this process and significantly abrogate virus 
production [48]. Furthermore, core protein dislocates a surface LD resident protein called 
adipose differentiation-related protein (ADRP) and leads to LD redistribution toward the 
nucleus in a microtubule- and dynein-dependent manner. 
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This redistribution was suggested to enhance encounters between the core and the 
replication complex during assembly [159]. Trafficking of core to LD also requires a 
mitogen-activated protein kinase called cytosolic phospholipase A2 enzyme (cPLA2) and 
diglyceride acyltransferase 1(DGAT1). Inhibition of the activity of cPLA2 or DGAT1 
inhibits virus production [160,161]. 
 
1.7.5.2 Nucleocapsid formation and genome encapsidation 
After accumulation of core around LD, core protein oligomerizes and binds viral RNA 
through its basically-charged domain D1 to form the nucleocapsid structure [49]. It is still 
unclear how the newly formed nucleocapsid packages the RNA genome. One possibility 
is that the delivery of viral RNA to the site of nucleocapsid formation and packaging is 
occurring via NS5A [47]. Consistent with this, NS5A was found to accumulate around 
LD through its N-terminal amphipathic helix and bind RNA through its zinc-binding 
domain [85,162]. Another potential explanation is that NS5A is acting only to deliver the 
viral RNA genome to the site of assembly and that the NS3-4A helicase activity binds 
RNA and serves to package it during nucleocapsid formation [32]. This notion was 
supported by the findings that the NS2 or NS2-p7 complex binds NS3 and this interaction 
mediates colocalization of these proteins to a site in close proximity to cLD [65,66]. 
Adding weight to this statement, it was found that mutations in the NS3 helicase domain 
enhancing RNA replication cause defects in virus assembly, highlighting a role of NS3 in 
the assembly process as a possible mediator of RNA packaging [32,163]. 
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Figure 1.4 Suggested model of HCV assembly and release. HCV is thought to 
initiate assembly in close association with LD. NS5A acts to deliver HCV RNA genomes 
to the site of assembly. Nucleocapsid RNA packaging is suggested to be accomplished by 
the viral protein NS3-4A complex. Consequently, the assembled capsid then buds into the 
lumen of the ER where glycoproteins E1/E2 reside. The orchestrating viral protein NS2 
serves to bring non-structural and structural proteins together to the site of assembly in 
collaboration with p7. The newly formed virion is secreted through the secretory pathway 
passing the Golgi network and the formed virion associated with VLDL particles is 
secreted out of the cell as viral lipoparticle (VLP). 
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1.7.5.3 Nucleocapsid envelopment 
A late step in the assembly process is the membrane envelopment of the newly-
formed nucleocapsid. Multiple studies have indicated that this step is tightly linked to the 
VLDL pathway [37,44,164-166]. VLDL formation starts with ApoB-100 synthesis 
through insertion of phospholipids and triglycerides from the cLD to the luminal side of 
ER membrane through the activity of the microsomal triglyceride transfer protein (MTP). 
This will lead to formation of a spherical like structure, termed the luminal LD (LLD), 
which then incorporates more triglyceride and Apo-E molecules to form mature VLDL. 
The mature VLDL’s then move to a distal compartment in the secretory pathway and are 
released from the cell (reviewed in [167]).  HCV formation is highly linked to this 
pathway due to the following observations: (i) fractionation of HCVcc-infected cells 
showed that HCV particles were found in detergent-resistant lipid fractions and were rich 
in similar VLDL lipid compositions [164,165]; (ii) HCV particles in infected patients 
were found to circulate as LVPs that are rich in triglycerides, and immuno-capture studies 
suggest that they contain Apo-B, Apo-E, and Apo-C along with the viral proteins core, E1 
and E2 [37,44,45,166,168]; (iii) chemical inhibition of VLDL pathway components, such 
as MTP, cPLA2 and DGAT1, as well as genetic silencing of Apo-E and Apo-B, 
significantly inhibits virus production [44,160,161,169], and (iv) most significantly, HCV 
particles in live cell imaging were found to colocalize with Apo-B in close proximity to 
LD and traffic with Apo-E to the cell periphery [170]. Taken in whole, the preceding 
evidence demonstrates the close association of HCV morphogenesis with lipid 
metabolism and suggests the assembly process likely hijacks the VLDL synthesis 
pathway.   
 
 
23 
 
The question remains: how are the envelope glycoproteins targeted to the assembly 
site and incorporated into the newly formed virion? E1 and E2 proteins form non-
covalent heterodimers that are retained in the ER lumen [171]. It was shown that NS2 
alone or the p7-NS2 complex modulates colocalization of the E1-E2 complex and NS3-
4A to LD by direct or indirect interactions [65,172,173]. Interestingly, a study 
investigating core protein trafficking in live virus-producing cells found that during the 
peak of virus assembly, core formed LD-independent puncta adjacent to the putative sites 
of assembly that traffic along microtubules [174]. Importantly, core was recruited from 
LDs into these puncta, and interaction between the viral NS2 and NS3-4A proteins was 
essential for this recruitment process [174]. Therefore, NS2-p7 might be orchestrating this 
step by interacting with NS3-4A in one manner to bring newly formed capsids to the site 
of assembly and with the E1-E2 complex in another way to facilitate the envelopment 
step (this model was suggested in [32]). 
1.7.5.4 Virus budding and release 
The virion forms by budding from the ER and egresses from the cell through the 
secretory pathway and is presumably released in a VLDL-dependent manner [175]. E1 
and E2 contain high mannose and complex N-linked glycans; these types of modifications 
are indicative of passage through the Golgi [176]. Supporting this idea, envelope proteins 
rearrange the disulphide bonds necessary to prime HCV particles for low pH-mediated 
fusion, similar to pestivirus egress through the Golgi [131,176,177]. The trafficking of 
HCV particles pre-envelope maturation is thought to be within intracellular vesicles. At 
this stage, the viral protein p7 ion channel activity was shown to protect nascent virions 
from low pH-mediated inactivation [178]. Contributing to this idea, a RNAi study 
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implicated SAR1A (a GTPase protein involved in membrane trafficking and found 
in COPII vesicles) in the production of extracellular HCV, suggesting HCV particles 
transport from the ER to the Golgi with COPII secretory vesicles [170]. Subsequently, 
virions are passaged from Golgi to the plasma membrane also through the secretory 
pathway as inhibition of the PI4KB (resident Golgi lipid kinase that is important in 
trafficking from the Golgi to the plasma membrane) significantly reduced the average 
velocity of motile labelled core puncta using live cell imaging [170]. Moreover, 
movements of the cytoplasmic labelled core puncta were dependent on NS2 function 
[170]. This evidence suggests a model of HCV trafficking that is highly dependent on the 
cellular secretory pathway and leads to acquisition of additional pH-resistance 
modifications in the viral envelope. Characterization of the envelopment process remains 
elusive, but the roles of p7 and NS2 have become increasingly conspicuous. 
Finally mature virions exit infected cells through the secretory pathway. The 
endosomal sorting complex required for transport (ESCRT) pathway is involved in 
membranous compartment fission that curves away from the intracellular cytosol [179]. 
This pathway is utilized by multiple enveloped viruses [179-182].  However, other studies 
showed that HCV particles are transported to the cell membrane through recycling 
endosomes that fuse with the plasma membrane to release virions into the extracellular 
milieu [170,183]. This could indicate that the ESCRT pathway is required for virus 
particle budding from the ER or virus trafficking into an intermediate secretory 
compartment. Endosome contributions may facilitate HCV particle movement to a cell 
junction protein domain and facilitate cell-to-cell spread [32,170,183]. Notably, the tight 
junction protein claudin 1 has been reported to be required for HCV cell-to-cell 
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transmission [184]. More analysis is needed to identify HCV release pathways and the 
possibility that HCV might spread through both extra-cellular release and cell-cell spread 
must be considered.  
1.8 HCV pathogenesis and immune-evading mechanisms 
1.8.1 HCV pathogenesis 
HCV-infected patients mainly acquire HCV infection by blood contact and, rarely, 
through sexual transmission. Thus, the main high risk groups are intravenous drug users, 
health care workers, and blood transfusion recipients before 1992 [185]. Within 
approximately 21 days after infection HCV RNA becomes detectable in serum [186,187]. 
Anti-HCV antibody detection normally occurs 32-46 days after viremia [188]. A small 
minority of patients spontaneously clear the virus to an undetectable level by the currently 
available clinical assays, while the majority (54-86%) develop chronic hepatitis [189]. 
Jaundice is the specific clinical sign of acute infection, but some patients develop 
nonspecific signs, which can include fatigue, nausea, mild fever, abdominal pain and loss 
of appetite [190]. The majority of patients remain asymptomatic during the acute phase of 
infection and, unfortunately, they do not become aware of the disease until much later in 
life [190]. 
It is still unclear why some patients eradicate the infection during the acute phase of 
the disease, but several factors have been postulated which include: (i) gender and age, as 
it was shown that women resolve acute hepatitis C  two times more often than men and 
acquiring infection at a younger age might facilitate viral clearance [190,191]. However, 
the underlying mechanisms are not clear and controversial findings have been published 
[192,193]; (ii)  a strong HCV-specific CD8+ T cell response is correlated with the control 
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of viremia during the acute phase of infection [194]; (iii) also, natural killer (NK) cells 
from HCV-infected patients, but not from healthy controls, overexpress inhibitory 
receptors and produce cytokines that attenuate the adaptive immune response, such as 
transforming growth factor-β (TGF-β) and interlukin-10 (IL-10) [195]. Genetic factors 
appear to contribute to NK cell activity. Allelic variation impacts expression of killer 
inhibitory receptors (KIRs) on NK cells and HLA expression on target cells, both of 
which play key roles in NK cell activation [196]. Furthermore, a high rate of self-limiting 
disease is associated with the presence of clinical symptoms during the acute phase of the 
disease and suggested that a stronger immune response arises in symptomatic patients 
[197], and (iv) certain single nucleotide polymorphisms (SNPs) in the IL28B gene that 
encodes interferon-lambda-3 were found to greatly contribute to both spontaneous 
clearance of HCV infection and response to interferon-based therapy [198,199]. 
However, the mechanism of IL28B SNPs in viral clearance and treatment response is still 
not clear. 
The chronic phase of the disease can be defined as a persistent infection in which 
HCV RNA remains detectable for longer than six months after transmission [200]. 
Chronic hepatitis C is accompanied by liver damage and may result in liver fibrosis, 
cirrhosis, and HCC [201]. It was assumed that liver injury during the chronic stage is 
immune-mediated due to the fact that T cell infiltration in the liver temporally correlates 
with the onset of liver injury [201]. However, rapid disease progression in 
immunodeficient patients or with therapeutic immunosuppression infers that additional 
factors are involved in liver injury [202]. In the HCVcc system, it was found that HCV 
replication induced cell death-related genes and caused apoptosis [203]. This notion was 
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supported by a study performed in chimeric mice with humanized liver and lacking an 
adaptive immune system (SCID/Alb-uPA), which also found that apoptosis was induced 
by HCV infection [204]. The observed apoptosis in SCID/Alb-uPA HCV-infected mice 
was mediated by a combination of induction of ER and oxidative stress and 
downregulation of the anti-apoptotic proteins nuclear factor-κB (NF-κB) and B-cell 
lymphoma-extra large (Bcl-xl) [204]. Analysis of liver tissue from patients with chronic 
viral hepatitis demonstrated upregulation of human serine/threonine kinase-1 (hSGK1) 
and signaling mediators of transforming growth factor-β (Smad), both of which are 
apoptosis markers and associated with TGF-β signaling [205,206]. Taken together, these 
findings suggested that HCV infection not only induces liver cell apoptosis, but also can 
induce fibrosis by activating TGF-β signaling, which lead to collagen deposition [207]. 
As disease progresses, fibrous bridges form between adjacent portal areas, which can 
lead to cirrhosis in around 15-56% of the patients with chronic HCV infection [208,209]. 
Activated liver stellate cells produce excessive amounts of extracellular matrix including 
collagen and are the main contributors in the development of cirrhosis [210].  HCC 
develops at a higher rate in cirrhotic HCV-infected individuals, but still can be detected in 
non-cirrhotic patients with advanced fibrosis [211]. The mechanism of HCC is poorly 
understood, but dysregulation of cell proliferation by HCV replication is probably 
essential for the immortalization of infected hepatocytes. It also was suggested that 
hepatocyte regeneration in an oncogenic environment containing mutagens, such as 
oxidants, which are present as a consequence of cell injury, fibrosis and immunological 
attack, can  result in the emergence of HCC [212]. The HCV core protein was shown to 
transform cells into a malignant phenotype through cooperation with transforming protein 
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p21 (H-ras) [213]. It has also been reported that other HCV proteins, such as NS3, NS4B 
and NS5A, have oncogenic potential, but the mechanism of involvement in cellular 
transformation and in vivo relevance remains to be defined [214-216]. Risk factors can 
also increase the incidence of HCC development, including co-infection with hepatitis B 
virus (HBV) or Epstein-bar virus (EBV) [217-219]. Genetic background is also another 
risk factor as a SNP in MHC class I polypeptide-related sequence-A (MICA) was 
strongly associated with the onset of HCC in HCV-infected patients [220]. All of the 
above, as well as other risk factors have been proposed, but the evidence is less clear and 
there is a lack of representative data. 
Chronic HCV infection may also cause extra-hepatic manifestations (EHM) with 40-
74% of infected individuals shown to develop at least one EHM [221,222]. Mixed 
cryoglobulinemia (MC) is the most commonly associated disorder with HCV infection at 
a rate of 19-55% [223]. Other EHMs were also reported, including lymphoma, 
glomerulonephritis, vasculitis,  insulin resistance and type 2 diabetes, and autoimmune 
disorders, such as thyroiditis, depression, anemia and impaired renal function [223-225]. 
One interesting observation is that HCV can also infect cells of the immune system [226-
228]. HCV RNA positive and negative strands, as well as viral proteins have been 
visualized in isolated peripheral blood mononuclear cells (PBMC) from chronically 
infected patients [226,228]. Multiple reports have described reactivation of HCV 
infection after SVR in immunological disorders such as HIV or 
hypogammaglobulinaemia [229,230]. In addition, immunosuppressive drug receipt has 
also been shown to associate with recurrent HCV infection despite an apparent SVR 
[231,232]. This idea is also supported by the above-mentioned association of HCV with 
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MC and non-Hodgkins lymphoma. HCV variants isolated from immune cells were 
different from those in serum or liver in infected individuals and from the JFH-1 strain 
obtained from HCVcc [233-236]. These differences where mapped to the 5′-UTR and 
promote HCV replication in immune cells but not in liver cells [237]. As a whole, these 
observations suggest that HCV infection of immune cells could be responsible for 
reactivation of HCV after SVR and HCV may undergo a latency-like stage during the 
course of infection or treatment period in what’s called occult HCV infection (OCI) 
[238]. However, the exact mechanism and role of OCI in disease progression and 
reactivation is still not clear and requires more investigation. Such findings are most 
important to understand mechanisms of HCV reactivation after apparently successful 
treatment.              
1.8.2 Mechanisms of immune evasion in HCV infection  
HCV has evolved several mechanisms to establish a persistent infection. The first line 
of defense that HCV evades is the innate immune response (reviewed in [239]). The viral 
protein NS3-4A was shown to cleave mitochondrial antiviral signaling protein (MAVS) 
both in cell culture systems and in infected patient hepatocytes [240]. MAVS is a part of a 
pattern recognition receptor (PRR) pathway that is important for sensing viral RNA and 
mounting an immune response [241]. RIG-I senses the pathogen associated molecular 
pattern (PAMP) in the HCV genome and activates a signaling pathway through MAVS 
leading to production of downstream effector molecules, such as interferon regulatory 
factor 3 (IRF-3), NF-κB and a variety of pro-inflammatory cytokines required for innate 
antiviral immunity and IFN production [241]. NS3-4A was also shown to degrade TRIF 
and inhibit RNA sensing through the RNA sensing PRR termed toll like receptor 3 (TLR-
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3) [75]. TLR-3 and its signaling through the adaptor protein TRIF activates IRF-3 and 
NF-κB for the production of IFN and inflammatory cytokines needed for proper immune 
system function, such as upregulation of the cytotoxic T cell response [242]. The viral 
proteins NS5A and E2 were shown to inactivate protein kinase R (PKR), an example of a 
non-traditional PRR that senses viral dsRNA [243-245]. NS5A and E2 can inhibit the 
kinase-dependent activity of PKR and lead to phosphorylation of eukaryotic initiation 
factor 2 alpha to suppress host mRNA translation, but not HCV translation [243-245]. 
NS5A and E2 suppress PKR kinase-independent activity as well, acting to inhibit 
induction of specific IFN-stimulated genes (ISGs) and IFN-β by signaling through MAVS 
before RIG-I activation [88,243-245]. However, HCV inhibition of PKR kinase-
dependent activity could limit host factors important for HCV replication. Therefore, it 
was suggested that NS5A and E2 PKR kinase-dependent inactivation functions at a 
specific time during infection to support availability of required host factors for HCV 
replication after NS3-4A-mediated inhibition of MAVS [239]. The core protein of HCV 
also contributes to the inhibition of innate immune responses by antagonizing IFN 
signaling through blockage of the Jak-STAT signaling pathway [239,246,247]. 
HCV can also evade components of the adaptive immune system directly. The high 
rate of HCV replication combined with the polymerase lack of proofreading helps the 
virus to escape the antibody response [248,249]. HCV escape mutations also inhibit 
CD4+ and CD8+ T cell responses by affecting  epitope processing, MHC binding, and 
recognition by both CD8+ and CD4+ T cells [248,250-252]. Fascinatingly, HCV-specific 
T cells isolated from blood and liver biopsies of infected patients express the inhibitory 
receptor programmed cell death-1 (PD-1), which inhibits effector functions and 
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accelerates apoptosis upon engagement with its ligand expressed on infected hepatocytes 
[253,254]. The effector function of HCV-specific T cells isolated from infected patients’ 
blood can be rescued by in vitro exposure to PD-1 blocking antibody and after blocking 
of cytotoxic T-lymphocyte antigen 4 (CTLA-4) and PD-1 for T cells isolated from liver 
biopsies [254,255]. Studies on HCV-specific CD4+ and CD8+ T cells found them to be 
impaired in their effector functions, such as cytotoxicity and production of effector 
mediators IL-2, TNF-α and IFN-γ [256-259]. The mutation rates and amino acid changes 
in HCV was found to be affected by immune responses, with the highest level of selective 
pressure peaking during the acute phase of the disease and decreasing gradually as the 
infection continues [248,251,260].  Therefore, T cell accumulation with a sequential loss 
of function could be a result of altered peptide ligands that downregulate T cell responses 
and fail to effectively prime new T cells during the course of infection leading to 
persistence of the pathogen [252,261]. 
1.9 HCV therapy 
Until recently, the standard treatment for HCV infection consisted of Peg-IFN-α and 
ribavirin [262]. Peg-IFN-α is a general antiviral agent supporting the immunological 
response, whereas ribavirin activity is not well defined [263]. Multiple mechanisms have 
been reported for the activity of ribavirin that include: induction of IFN-stimulated genes 
(ISGs); enhancement of the Th1 immune response; inhibition of HCV NS5B polymerase 
activity; and GTP depletion by inhibiting inosine monophosphate dehydrogenase [263]. 
This treatment combination led to a SVR of about 50% for patients infected with G1 and 
G4, and about 80% for G2- and G3-infected patients [5,264]. Sadly, this treatment 
combination is associated with severe side effects, including fatigue, flu-like symptoms, 
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mild anxiety, skin rash, nausea, diarrhea, autoimmune diseases, hemolytic anemia, 
depression, and other neuropsychiatric side effects [265,266]. True selection of viral 
resistance to Peg-IFN-α and ribavirin treatment has not been observed. 
Since 2011, standard HCV therapy against infection with G1 has been updated to 
include Peg-IFN-α, ribavirin and one of two DAA compounds targeting the NS3-4A 
protease in a triple therapy approach [6,7]. The 1st generation NS3-4A protease inhibitor 
telaprevir and boceprevir increase the SVR rate from 50% to 70% but are unfortunately 
associated with viral resistance and severe side effects [6,7]. A number of other 1st 
generation protease inhibitors, such as simeprevir, vaniprevir, asunaprevir and faldaprevir 
are in clinical development and showed more antiviral activity with milder side effects 
[8,267]. These 1st generation protease inhibitors, dependent on class, show overlapping 
resistance profiles and a limited genotype coverage [8]. The 2nd generation protease 
inhibitors MK-5172 and neceprevir showed higher antiviral activity and a broader 
genotype coverage with favorable resistance profiles. Both are currently under 
development [268]. 
Other DAA compounds targeting viral proteins other than NS3-4A were also 
developed. The nucleoside inhibitor sofosbuvir targets the NS5B polymerase active site 
and showed 90% SVR as determined by clinical HCV RNA detection assays and 
satisfactory safety profiles [269,270]. The nucleoside inhibitors have pangenotypic 
coverage and a high barrier to resistance due to their mechanism of action [267]. NS5A 
also emerged as a DAA target with the antiviral compound daclatasvir showing the most 
promise [271]. Daclatasvir showed broad genotypic activity, reduced HCV infectivity 
with sub-micromolar concentrations in cell-based assays, and rapidly reduced circulating 
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HCV in clinical trials [271-273]. This compound has a low barrier to resistance [272]. 
The idea of using daclatasvir in combination with other DAA classes such as sofosbuvir 
has been tested with promising results and is likely going to be used in combination 
approaches with other DAAs in the hope that an IFN-free all-oral combination may 
eventually become the standard of care [274]. 
One of the strategies used to develop HCV treatment is through targeting cellular 
proteins involved in HCV propagation inside an infected cell; such compounds are termed 
host-targeting agents (HTAs) [275]. For example, the small molecule ITX 5061, which 
inhibits HDL uptake by the liver through the SR-B1 receptor, was shown to inhibit HCV 
entry and is currently in phase 2 clinical trials [276]. Mutations in E2 HVR-1 can confer 
resistance to ITX 5061 [277]. Cyclophilin A (CypA) is an intracellular factor found to 
bind NS5A and important for HCV replication [153]. Alisporivir is a CypA inhibitor that 
demonstrates potent antiviral activity and enhances IFN-based treatment, but is associated 
with acute pancreatitis among trial participants and is now on clinical hold [278-280]. 
Another promising host factor target required for HCV replication is the liver-specific 
miR-122 [281]. MicroRNAs are small RNA sequences required to reduce the level of 
host translated proteins through interaction with messenger RNA (mRNA), thus 
regulating host gene expression [282]. In the case of HCV infection, miR-122 interacts 
with the HCV genome at the 5′-end and enhances HCV replication [281]. This interaction 
was also suggested to protect uncapped HCV RNA from degradation by cellular 
exonucleases and shield the 5′-end of the genome from recognition by PRRs [283,284]. A 
small complementary sequence antagonizing miR-122 (antagomir or miravirsen) 
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significantly inhibits HCV viral load after subcutaneous injection of miravirsen in the 
chimpanzee model and infected humans, and is now in clinical development [285,286]. 
In addition to DAAs and HTAs, HCV vaccine development is also under way, where 
such achievement will be of outstanding value towards HCV eradication. HCV 
neutralization antibodies against E2 protein derived from hyper-immunized rabbits were 
shown to prevent HCV infection of chimpanzees [287]. However, antibody-based 
vaccines fail due to HCV mutations and cell-to-cell transmission where virions are hidden 
from neutralizing antibody contact [184,287]. It remains possible that a cloned pool of 
antibodies can be used as post-exposure prophylaxis treatment [288]. DNA vectors 
encoding E1, E2, core, NS3 or NS3-NS5B were also investigated in infected chimpanzees 
as a strategy to elicit strong T cell responses and develop a protective HCV vaccine [289-
292]. However, the observed protection in these vaccination strategies was short in 
duration and could not prevent HCV infection after rechallenge. 
Treatment of HCV improved after the approval of the first two DAAs. A collaborative 
effort of basic understanding of the HCV life cycle, industrial drug development and 
clinical investigations provide hope for identifying novel therapeutic agents that can lead 
to HCV eradication. 
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1.10 The HCV protein p7 
The review of the HCV p7 protein below has been published in Virology as an Invited 
Review. 
1.10.1 HCV p7 processing, topology, and localization 
The p7 protein was identified through expression of a series of C-terminally truncated 
HCV polyproteins fused to a human c-myc epitope tag. This analysis located p7 between 
the envelope glycoprotein E2 and the NS2 protein (Figure 1.1) [137]. Homologous 
proteins have been identified in the Pestivirus genus, e.g., bovine viral diarrhea virus 
(BVDV), classical swine fever virus, and border disease virus, all containing such a 
characteristic protein between E2 and NS2 [293]. However, Flaviviruses such as yellow 
fever virus, dengue virus, and West Nile virus do not encode a protein homologous to p7 
[294]. 
Upon HCV genome translation, p7 processing is mediated by host-encoded proteases 
(Figure 1.1) [19,295], but scission at the E2-p7 and p7-NS2 junctions is delayed, resulting 
in the presence of precursor E2-p7-NS2 polyproteins. The cleavage at the E2-p7 junction 
is incomplete and performed by a unique mammalian signal peptidase leading to the 
presence of E2 and p7 mature forms, as well as some E2-p7 species [137,139,171]. Partial 
cleavage was attributed to a structural determinant located N-terminal to the signal 
peptides. This is supported by the finding that fusion of reporter proteins N-terminal to 
the signal peptides improves cleavage efficiency [296]. The function of E2-p7 or p7-NS2 
precursors is yet unidentified, but hypotheses have been developed: (i) the precursor itself 
plays a role in the HCV life cycle; (ii) the precursor could be important for regulating the 
kinetics and/or levels of final product expression to prevent premature virus assembly 
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[296,297] (such a case was illustrated in the coordinated cleavage of C-preM in the 
Murray Valley encephalitis virus  [298]); (iii) the E2-p7 precursor might be important for 
pulling p7 into the physical composition of the virion by retaining a pool in the ER as the 
E2-p7 form [299]. However, it’s likely that cleavage of E2-p7 precursors play a 
regulatory role because complete separation of E2 and p7 by insertion of an 
encephalomyocarditis virus (EMCV) IRES between these two proteins moderately 
reduced the level of virus production in the HCVcc system. This suggests the E2-p7 
precursor serves no functional purpose on its own, but that a temporal dependence on E2-
p7 processing is critical for virus production [297,300]. In trans-complementation studies, 
it was found that whether p7 alone or p7 in the context of cleavage intermediates were 
sufficient for restoration of virus production depended on the extent of the original p7 
deletion and the degree of indirect effects such deletions had on polyprotein processing. 
[301]. In summary, it is clear that the p7-including processing intermediates in some way 
impact virus production, but whether these intermediates have specific functions within 
the viral life cycle requires further investigation. 
The p7 protein is a polytopic membrane protein that crosses the ER membrane twice, 
forming trans-membrane domain 1 (TM1) and trans-membrane domain 2 (TM2) 
connected by a short segment (Figure 1.5), with its N- and C-termini oriented toward the 
cytosol [137]. The subcellular localization of p7 was identified by fusion of p7 to CD4 or 
Myc. These fusions in HepG2 cells identified a large fraction of p7 in an early 
compartment of the secretory pathway suggesting the presence of a retention signal 
maintaining localization of p7 in the ER [302]. Conversely, intracellular staining of green 
fluorescent protein (GFP) or Flag-tagged p7 in 293T cells showed that p7 partially co-
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localized with mitochondria and adjacent membrane structures [303]. Interestingly, 
staining of native and tagged p7 demonstrated that untagged p7 was exclusively detected 
on the ER, while N-terminally tagged p7 was detected on ER or mitochondrial adjacent 
membranes. This work is indicative of complex trafficking of p7 that could be regulated 
by the cleavage from its upstream signal peptide and targeting signals present within the 
protein sequence. Transmission of calcium ion fluxes from ER cisternae to mitochondria 
has been shown to be a pivotal process in the regulation of apoptotic signaling. Therefore,  
The authors suggested that p7 association with ER and mitochondrial membranes may 
interfere with such signals, rendering the cell insensitive to proapoptotic stimuli from 
immune cells or the effects of other viral gene products [299,304]. Immunofluorescence 
(IF) and electron microscopy (EM) in the context of a full-length, RNA replication-
competent HCV genome derived from the JFH-1 sequence, showed that GFP-p7 or p7 
fused to human influenza hemagglutinin-tag (HA-tag) 4 amino acids downstream of the 
potential E2-p7 cleavage site were localized only at the ER in Huh7 cells. However, it is 
important to note that these tags likely disrupted virus production [305]. Consequently, 
recent studies have double-HA-tagged p7 at the N-terminus in the chimeric virus Jc1, 
creating a viable virus. This replicating virus showed significant colocalization of p7 with 
ER markers and a lesser extent of association with mitochondrial or LD markers. p7 
showed a reticular staining pattern that mainly co-localized with HCV E2 and partially 
with NS2, NS3, and NS5A [306]. Hypothetically, p7 localization with multiple organelles 
may be indicative of this protein’s dual role in HCV assembly and trafficking of nascent 
virions through multiple cellular pathways. 
 
 
 
38 
 
 
 
 
 
 
 
 
 
B. 
 
 
 
 
 
Figure 1.5 p7 topology and sequence analysis. (A) Representative diagram of p7 
topology within the ER showing the TM1 and TM2 connected by a cytoplasmic loop. 
Both N- and C-termini are oriented toward the ER lumen. (B) Examples of commonly 
used isolates with genotype/subtype sequence variability and domain locations shown. 
TM1 (aa13-32) and TM2 (aa38-57) are indicated by dark gray boxes. The two conserved 
basic residues in the cytoplasmic loop are shown in red. 
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The relatively small size of p7 and its membrane integration topology have made 
analysis of localization and function laborious and sometimes inconclusive. It is possible 
that the accessibility of antibodies or the duration of infection chosen in the above-
mentioned literature inaccurately identified localization of p7 in multiple cellular 
compartments. Therefore, more sensitive proteomic analysis for p7 tracking and 
localization on multiple separated cellular organelles at various times during HCV 
infection in cell culture is needed in order to gain more reliable insights into the role(s) of 
p7 in the HCV life cycle. 
1.10.2 Ion channel function and potential anti-p7 compounds  
The p7 proteins of BVDV and HCV were originally proposed to oligomerize and form 
ion channels by Harada et al. [307] and Carrere-Kremer et al. [302], respectively. 
Oligimerization was observed when it was shown that p7 formed a hexamer in artificial 
membranes and functioned as a calcium ion channel in so called black lipid membranes. 
The ion channel activity of p7 in this assay could be abrogated by the drug amantadine 
[308]. The ion channel activity of a cross-linked p7 led to inclusion of this protein in the 
viroporin family, which consists of small hydrophobic proteins with the ability to 
permeabilize membranes for ion and small molecule movement (examples are listed in 
Table 1.2 and reviewed in [309-313]). An important example is the viral protein M2 of 
influenza virus, which forms proton ion channels and is activated in acidic environments. 
M2 triggers viral uncoating during entry within acidic endosomes and protects the HA 
glycoprotein from premature maturation in the trans-golgi network during egress, 
indicating that a multitude of functions can be performed by virally encoded ion channels. 
The channel activity of M2 is blocked by amantadine and rimantadine, suggesting the two 
 
 
40 
 
could be used to treat influenza infection (reviewed in [314,315]). p7 conductance across 
artificial lipid membranes was confirmed when pentamer formation was shown to be 
necessary for accommodation of ion transport. This study also reported a concentration-
dependent inhibition of p7 channel activity after treatment with long-alkyl-chain 
iminosugar derivatives, such as N-nonyl deoxygalactonojirimycin (NN-DGJ), N-nonyl 
deoxynojirimycin (NN-DNJ) and N-7-oxanonyl-6-deoxy-DGJ [316]. These compounds 
were tested because of their potent anti-viral activity against BVDV [317]. 
In cell-based assays, Griffin et al. demonstrated that expression of p7 in mammalian 
cells can substitute for influenza virus M2 channel activity to maintain infectivity of 
influenza, and that this activity also could be blocked by the antiviral drug amantadine. In 
addition, it also was shown that mutation of the two basic residues within the p7 
cytoplasmic loop abrogated ion channel activity, highlighting the importance of this loop 
for p7 function [303]. A subsequent study confirmed the ion channel function of p7 in 
planar lipid bilayer membranes and showed that p7 channels were permeable to 
potassium and sodium ions, with limited permeability to calcium ions [318]. Later, 
fluorescence-based liposome assays were developed to more conveniently assay for p7 
channel activity and therapeutic targets within p7. Employment of such assays using p7 
from genotype 1b showed a dose-dependent release of fluorescent indicator when mixed 
with liposomes. The release activity was blocked by the drugs amantadine, rimantadine 
and several related compounds [319]. Taken together, these similarities with M2 protein 
function and inhibition provide strong evidence that p7 is also a viroporin. 
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Table 1.2 Examples of known viroporins 
 
Ion channel names and their respective virus and family names are shown (1st and 
2nd columns). The known or expected functions are listed (3rd column). The number of 
monomers needed to form the channel upon oligomerization and the classification (class) 
are shown (4th column). Potential inhibitors (5th column). Abbreviations: HA: 
hemagglutinin, HIV-1: Human immunodeficiency virus type 1, Vpu: viral protein U, 
CoV: coronavirus. (Table information is gathered from references [309-313]). 
 
 
Viroporin 
 name
 Virus family  Main function Oligomerized 
 state/Class  
 Inhibitors
Influenza A 
 M2
 Orthomyxoviridae 1.  Viral genome uncoating.
2. Assembly of functional    
 HA conformation. 
 Tetramer/Class IA Amantadine and 
 Rimantadine
 HIV-1 Vpu  Retroviridae 1. Facilitate budding of newly   
 formed virion.
2. Enhance degradation of 
 CD4. 
 Pentamer/Class IA Hexamethylene 
amiloride, 
 BIT225
Picornavirus 
 P2B
 Picornaviridae Modulate virus release and 
host cell apoptosis 
 (suggested)
Dimer or tetramer/ 
 Class IIB
DIDS (classic 
anion exchanger 
inhibitor) tested 
only in 
 Enterovirus
 CoV-E  Coronaviridae 1. Induce assembly by 
enhancing membrane 
 scission.
2.  Induce virion release.
Dimer, tetramer, or 
 pentamer /Class1A
Hexamethylene 
 amiloride
 
 
42 
 
Investigation of sequence determinants in p7 critical for ion channel activity or drug 
sensitivity led to a number of insightful outcomes concerning the role of the putative 
channels. One report showed that the leucine-rich motif at the C-terminal end of TM2 
partially contributed to drug sensitivity. Mutation of the two basic residues within the 
cytoplasmic loop (K33/R35 in G1b) was found to affect channel activity and caused 
disruption of the ion channel insertion into membranes. The histidine at residue 17 in 
TM1 also showed significant effects on ion channel function [320]. H17 is part of a 
HXXX(Y/W)-like motif that is also found in influenza M2 and is integral for ion channel 
opening [321]. H17 was shown to be in a critical position in the ion pore, demonstrating 
its key role in ion channel conductance [322]. Additionally, the L20F mutation and F25A 
polymorphism in HCV p7 were found to confer adamantane and iminosugar resistance, 
respectively [323]. These findings highlight the importance of mutational analyses of the 
p7 sequence and the associated ion channel activity, with major implications on drug 
binding and potential identification of novel inhibitors. 
p7 channel activity had never been tested in a cell culture-based assay recapitulating 
the entire HCV life cycle because such a system (HCVcc) was not established until 2005 
[324-326]. In contrast with earlier studies, discrepancy was observed when the HCVcc 
system was employed to characterize the potential antiviral effects of amantadine and 
iminosugar derivatives (NN-DGJ, NN-DNJ and NB-DNJ). It was found that amantadine 
did not affect virus release, infectivity or ion channel activity of JFH-1 (G2a) or chimeric 
HCV genomes (H77 (G1a), Con1 (G1b), and J6 (G2a)). In contrast, the iminosugar 
derivatives reduced virus titers in a dose-dependent manner in the context of multiple 
genotypes, primarily at virus assembly or release steps [327]. The iminosugar derivatives 
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NN-DGJ, NN-DNJ and NB-DNJ have been shown also to target cellular α-glucosidase I 
and II, and their inhibition leads to misfolding of various host [328] and viral 
glycoproteins, such as BVDV E2 [329] and gp120 of HIV [330]. With this in mind, the 
above-mentioned effect of iminosugar derivatives on virus production could be attributed 
to alteration in HCV envelope proteins, as shown previously [327], or to a manipulation 
of a host cellular glycoprotein crucial for virus propagation in cell culture. Similar 
discrepancy was also observed in a related protein called p13-c of GBV-B, whereby 
amantadine inhibited the function of p13-c ion channel activity but failed to inhibit 
replication and secretion of GBV-B from virally-infected marmoset hepatocytes [331]. 
The development of the HCVcc system introduced greater opportunities for p7 
characterization. Griffin et al. extensively differentiated the genotype- and subtype-
dependent sensitivity of p7 to multiple inhibitors using both HCVcc and artificial 
membrane assays. It was found that p7 from the JFH-1 isolate was not blocked by 
amantadine in HCVcc or liposome-based assays, whereas amantadine successfully 
inhibited G3a in both systems. Amantadine inhibits J4 (G1b), while rimantadine was able 
to inhibit both JFH-1 and J4 channel activity and virus production. In addition, the 
iminosugar derivatives NN-DGJ and NN-DNJ reduced infectious virus production for 
genotype 2a and 1b in a dose-dependent manner, with no observed effect on viral protein 
synthesis, processing, HCV RNA replication or cellular cytotoxicity [332]. Until now, 
differing results have been obtained with various inhibitors in the context of different 
genotypes. These contrasting results suggest that p7 inhibitors may need to be developed 
in a genotype-specific manner. 
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Interestingly, p7 ion channel activity was identified in native cell membrane vesicles 
and infected Huh-7.5 cells by measuring H+ proton conductance and fluorescent detection 
of lysosomal pH indicators. Similarly, expression of p7 in HEK-293FT cells equilibrated 
H+ conductance. HCV infection increased lysosomal pH in infected cells, but defective 
ion channel mutants yielded no such increase. Furthermore, amantadine, rimantadine and 
hexamethylene amiloride block H+ conductance through native vesicular membranes 
[178]. In a very recent article, Atkins et al. provided new evidence suggesting that p7 
directly influences the stability of secreted, acid-labile HCV particles via an as yet undefined 
mechanism [333]. This strongly advocates the importance of ion channel activity during 
virus propagation. 
A small compound termed BIT225 was shown to inhibit HIV production at a late 
stage in the viral life cycle by blocking Vpu ion channel activity and impeding virus 
release from monocyte-derived macrophages [334]. BIT225 was also shown to bind p7 
using a computational model of a p7 monomer, along with amantadine, rimantadine and 
NN-DNJ [335]. BIT225 was shown to inhibit p7 ion channel activity in lipid membranes 
and demonstrated antiviral activity in a BVDV infection assay [336]. 
A small number of clinical trials that included potential p7 inhibitors have been 
performed to date. Combination therapy of amantadine and IFN-α exhibited an 
insignificant correlation between amino acid variation within p7 and response to 
treatment in G1a/b-infected individuals. However, a L20F mutation was observed more 
often in non-responder patients infected with G1b receiving this combination therapy, 
which gives weight to the theory that amantadine targets p7 [337]. Subsequently, an 
increase in early anti-virological response was observed in G1a/b patients treated with 
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IFN-α, ribavirin and amantadine, yet sustained virological response rates remained the 
same as in the arm receiving standard of care [338]. Such early inhibition was observed 
previously when a combination of amantadine, ribavirin and IFN-α was shown to reduce 
plasma viral RNA levels in patients in a phase 1 trial [339]. These data suggest that 
amantadine could be useful in the case of new infections or to promote viral decay before 
the establishment of chronic infection. 
It is still premature to include an ion channel inhibitor with IFN-α and ribavirin. The 
discrepancies observed among the inhibition studies performed to date could be attributed 
to system inconsistencies, e.g., artificial membrane, liposome assay or HCVcc, and/or use 
of dissimilar p7 genotypes studied in native form versus tagged versions of the protein. 
Clinical trial data is still confined to response rates and lack of some aspects of drug 
delivery analysis is plausibly accountable for the minimal therapeutic outcomes. 
Completion of extensive mutational analyses on p7 could further our structural and 
functional understanding of the ion channel and identify specific regions within p7 that 
could represent novel therapeutic targets. Subsequent or concomitant analyses of patient 
genomes from clinical trials could provide penetrative information concerning resistance 
and susceptibility in the p7 region.   
1.10.3 NMR analyses of p7 
Nuclear magnetic resonance (NMR) structural analysis performed on p7 from G1b 
showed that the N-terminal portion formed an α-helix (aa 1-14) and TM1 (aa 15-18) and 
TM2 (aa 19-32) formed α-helixes connected by a short loop (aa 33-39) [340]. However, 
the structural features and the helix lengths observed through NMR conflicted with the 
molecular model of p7 [302,320,341,342]. The monomeric NMR structure of p7 unveiled 
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a dynamic nature, and the structure identified predicted a multifunctional protein rather 
than one strictly acting as an ion channel [343]. Also, monomeric NMR structural 
analysis performed on Flag-p7 from G1b identified a relevant allosteric cavity compatible 
with drug binding. These findings highlight the importance of p7 as a potential target for 
the development of HCV inhibitors [344]. 
NMR data obtained on oligomerized p7 indicated that the protein forms a hexameric 
channel complex in the presence of detergent, and EM analysis identified a flower-like 
shape with six distinctive petals with the p7 helices oriented toward the lumen of the ER. 
The identified structure also showed an accessible area facing the interior of the ER that 
could provide an interaction face with other viral or host proteins [345]. Additionally, the 
G1b p7 sequence can assemble sequentially to form an oligomerized structure of four to 
seven subunits with the most putatively functional oligomer being the hexamer in which 
the cylindrical structure accommodates the flower-like shape. The sequential formation of 
the channel was suggested to regulate the function of p7, whereby p7 would be retained in 
an inactive state that allows p7 to bind to other viral proteins early in the assembly 
process. Subsequently, pore formation could take place to accommodate channel activity 
required at a later stage in the life cycle [346]. A more recent NMR structural 
identification of the p7 ion channel showed that the G5a sequence forms an unusual 
hexameric complex with a funnel-like shape. This study also suggested that amantadine 
and rimantadine bind to six equivalent hydrophobic pockets between the pore-forming 
and peripheral helices, defining a possible mechanism of inhibitory action [347]. 
The diversity of structural predictions for p7 based on NMR analyses may be 
attributed to a number of variables, such as the different genotypic p7 amino acid 
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sequences, the purification method used, or the solvent and environmental conditions 
used in the preparation of the protein for NMR structural analyses. However, structural 
agreement in NMR studies will prove to be important for identification of structural 
features of monomeric and oligomeric p7 structures, as well as drug binding determinants 
within p7. 
1.10.4 Functional analyses of p7 
In 2003, deletion or mutations at the two conserved positively charged residues in the 
cytoplasmic loop of p7 within infectious clones of G1a failed to cause viremia after 
intrahepatic transfection in the chimpanzee model. Furthermore, substitution of G1a p7 
with p7 from an infectious G2a clone was also not viable. These results clearly 
demonstrated the importance of p7 for the virus life cycle in vivo, as well as the restrictive 
genotypic context of p7 function [348]. Given the accumulating evidence suggesting that 
p7 forms an ion channel and acts as a viroporin, it is conceivable that such an activity 
might be required for the virus to facilitate entry, assembly or release in a manner similar 
to that of other viroporins [308,316,318]. 
After the development of the HCVcc system, mutagenesis studies on various viral 
proteins for functional analysis became possible [324-326]. Early mutational analyses 
demonstrated the importance of p7 for virus production [300,349]. Steinmann et al. 
showed that p7 is involved at a late stage of the replication cycle, since mutants in p7 
reduced both total infectivity and the ratio of intracellular to released infectious particles. 
Successively, p7 was shown to be less likely involved in the viral entry process due to the 
maintenance of specific infectivity observed in released virions from genomes mutated in 
p7 [349]. A subsequent study illustrated that p7 mutant genomes generated lower levels 
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of intracellular virus, released core protein and infectious particles in the culture 
supernatant, suggesting involvement of p7 at an early stage of the viral morphogenesis 
cycle [300]. 
Currently, a number of convincing pieces of evidence exist suggesting that p7 is not 
involved in the entry steps of the viral life cycle: (i) HCV pseudoparticles (HCVpp) 
produced from 293T cells lack p7 but remain infectious to hepatocyte-derived cell lines 
[350]; The pseudoparticle system (HCVpp) exploited retrovirus biology to create 
retroviral particles with HCV glycoproteins expressed on the surface. 293T cells were 
used for generation of particles expressing E1 and E2, these particles could then be used 
to infect permissive hepatocytes and entry could be measured through the use of a 
luciferase or GFP reporter genes in the recombinant construct [350,351] (ii) cis-
expression of p7 during HCVpp production did not increase infectivity [352]; (iii) HCV 
virions are acid-resistant, suggesting that ion channel activity during entry is not needed 
[131]; (iv) p7 from the related virus BVDV was not found to be a component of the virion 
structure [293], and (v) more importantly, using an infectious construct containing a 
double HA-tagged p7, it was found that p7 was not contained within the virion, even in 
concentrated, affinity-purified or Flag-tagged preparations of virus [306]. All things 
considered, a viroporin-like activity of p7 might be required at a step downstream of virus 
entry that resembles the influenza A M2 activity during viral egress and HIV-1 Vpu (see 
Table 1.2). 
Regarding steps subsequent to viral entry, current evidence indicates that p7 has no 
role in RNA replication. Firstly, replicons lacking p7 replicate efficiently in Huh-7 cells 
[353,354], secondly BVDV containing mutations in p7 was able to replicate in cell 
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culture, but failed to produce infectious particles [307], and lastly mutations or deletions 
within p7 generated in the context of HCVcc replicate RNA efficiently with impaired 
infectious virus production [300,349]. 
Since the establishment of the HCVcc system, HCV assembly has been under intense 
investigation. One intriguing aspect of the assembly mechanism is the accumulation of 
core protein around a cellular organelle termed the LD, which is proposed to function as a 
platform for virus assembly [96]. However, others have suggested that core does not 
accumulate on LD in the context of an efficiently-assembling virus, suggesting that 
core/LD accumulation is an indication of an assembly defect [355]. It is worth mentioning 
that an NS2-mutated, assembly-deficient HCV strain could be rescued by compensatory 
mutations in p7 that restored virus production and colocalization of NS2, E2 and NS3 to a 
site in close proximity to LDs [65]. Likewise, another report visualized that p7 can 
manipulate the intracellular distribution of NS2 and disrupt its binding pattern with other 
viral proteins [172]. This assumption was confirmed recently by showing that NS2 
distribution is affected by the presence of p7 and its N-terminal signal peptide [356]. 
Presenting a different perspective, the efficiency of core accumulation on LDs due to p7 
mutations was quantified and it was found that mutations in the p7 cytoplasmic loop 
affected the unloading of core protein from LDs, resulting in a retention of core around 
LDs [30]. The preceding observations could indicate that p7 is important for 
colocalization of NS2 with LDs, a process that is crucial for NS2 function. Interestingly, 
p7 has been also shown important for unloading of newly-formed capsids toward further 
assembly, maturation and envelopment [30,357]. 
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Subsequent to core protein recruitment to LDs, core oligomerizes to form capsid 
structures. This presumably facilitates the formation of multi-order forms during the 
morphogenesis cycle that would include monomeric core, partial oligomers, fully 
oligomerized capsids and virions associated with triglycerides and β-lipoproteins, all of 
which would show different densities upon intracellular lysate fractionation [41,358,359]. 
A study has shown that mutated p7 at the cytoplasmic loop did not prevent the assembly 
of core-containing intracellular particles after iodixanol equilibrium gradient 
sedimentation [360].  Compellingly, another report performed core quantitation on the 
fractions obtained after sucrose-based rate zonal fractionation and observed an increased 
proportion of incompletely assembled capsids. Further analyses on these fractions 
indicated that p7 mutations or deletions in the cytoplasmic loop led to accumulation of 
non-enveloped capsids in transfected cells [30]. These data reflect the necessity of p7 
downstream of capsid formation. 
The postulate that p7 can function as an ion channel gained momentum when it was 
shown that HCV infection equilibrates intracellular acidic vesicles. This loss of acidity 
was not observed with HCV genomes harboring p7 ion channel defective mutations 
(KR33/35AA in the J4 sequence or RR33/35AA in JFH-1). It was found that intracellular 
HCV virions were acid-sensitive, whereas extracellular virions were acid-stable. In 
confirmation of this finding, the acidification inhibitor Bafilomycin A1 was able to rescue 
virus production of ion channel defective mutants in Huh-7.5 cells [178]. Furthermore, 
HCV replication-defective viruses containing mutations in TM1 of p7 or the cytoplasmic 
loop showed a restoration of infectivity by in trans expression of the M2 proton channel 
of influenza A, indicative of an ion channel requirement for HCV propagation in cell 
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culture [360]. Interestingly, proteinase K digestion of p7 mutant viruses showed 
significant reductions in core protein, indicative of nucleocapsids lacking envelopes, 
which demonstrated that p7 affects virus production at a step prior to envelopment [30]. 
p7 ion channel activity could be an important step to protect the immature virion from an 
acidic environment during the late stage of assembly, particularly at the envelopment 
step. 
In summation, therefore, it seems that p7 function may be two-fold: protection of 
virion-associated E2 from acid-induced degradation that is mediated by the ion channel 
activity; in the second role, p7 is required for proper targeting of viral glycoproteins 
through a concerted effort with NS2. A third potential function, which has received little 
attention to date, is that p7 may play a role in an interaction with a cellular factor. In this 
regard, p7 has been suggested to modulate cell death signaling and may be targeted by 
cellular kinases [361,362]. It would be interesting to know if p7 interacts with cellular 
proteins in order to promote virus production. 
1.10.5 p7 interactions with other viral proteins     
The binding pattern of p7 with other viral proteins is continually being revealed 
through genetic-based investigations and protein-protein interaction analyses. The first 
clue concerning the necessity for p7 to interact with other proteins came through 
intrahepatic RNA injection of chimpanzees with a chimeric virus generated by replacing 
the p7 sequence from G1a with that of G2a. The resulting chimera was not viable after 
injection, illustrating p7’s genotype-specific interactions [348]. The JFH-1 infectious 
clone was used in multiple studies to generate infectious chimeras by replacing the core-
NS2 (or in some cases core to part of NS2) fragment of the JFH-1 sequence (G2a) with 
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that of other genotypes. In this case it was observed that chimeric viruses were only 
viable when there was genotypic homology between p7 and the substituted structural 
genes. This characteristic of chimera construction suggested there is an important 
interplay between p7 and one or more structural proteins [23,60,363]. To successfully 
create a viable chimeric construct, H77 (G1a) was fused to JFH-1 (2a) at a site within 
NS2 and passaged to allow accumulation of adaptive/compensatory mutations. The 
resulting chimera acquired mutations within p7, NS2, E1 and NS3. The combination of 
p7 and NS2 mutations increased specific infectivity, suggesting an interaction between p7 
and NS2. This interaction was proposed to anchor p7 to NS2 within the membrane, 
thereby enhancing the ability of p7 to protect the nascent virion from premature 
inactivation [363]. Furthermore, compensatory mutations in p7 (F776L/S) significantly 
enhanced the fitness of defective core mutants in the context of a J6/JFH-1 chimera, 
providing genetic evidence for an interaction between p7 and core [364]. Taken together, 
it remains unlikely that a protein the size of p7 interacts with multiple viral proteins. That 
being said, it is possible that p7 interacts with a single viral protein in order to stabilize 
other downstream interactions and promote viral propagation. 
Biochemical and proteomic assays have also been used to identify p7 binding 
partners. One report that utilized tagged NS2 showed efficient pull-down with p7, E2, 
NS3 and to a lesser extent, NS5A [65]. Other work has shown NS2 can be co-
immunoprecipitated with E1 as well [172]. Importantly, mutagenesis studies have 
demonstrated that p7 affects NS2 colocalization with E2 and NS3 around LDs, and p7 
basic loop mutations significantly reduced NS2 interactions with E1, E2 and NS3 
[65,172]. It is noteworthy that mutations in the two basic residues of the cytoplasmic loop 
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of p7 caused considerable alteration of the intracellular distribution of NS2 and E2 [172].  
However, it is difficult to conclude whether these results indicate a direct interaction with 
the loop, or if the removal of the charged residues changed the topology of p7 to 
indirectly affect the localization of other proteins. Recently, NS2 was confirmed to 
interact with p7 and E2 as mutations in p7 changed subcellular localization of NS2 and 
reduced viral assembly [357]. p7 interaction with NS2 was shown to be independent of p7 
ion channel activity and NS2 localization was affected primarily by p7 and its signal 
peptide at the N-terminus, suggesting an alternative function of p7 during the assembly 
process [356]. More recently, a co-immunoprecipitation study using a replication-
competent virus containing a double HA-tagged p7 confirmed the specific interaction 
between p7 and NS2, which was proposed to be critical for virus production in cell 
culture [306]. Despite the discrepancies observed for NS2 as a p7 binding partner we can 
conclude that NS2 maintains the organization of the viral assembly process and that p7 is 
a mandatory interaction partner. It is also plausible that p7 binds NS2 in a manner that 
regulates its function in virus assembly. 
The size and topology of p7 has made it poorly immunogenic for antibody production. 
Consequently, the determination of p7 binding partners by standard methods is 
problematic and difficult to interpret. The topology of p7 in membrane structures and data 
generated from purified or tagged proteins might not reflect the actual picture. 
Considering p7 exists as multiple forms: unprocessed E2-p7, p7-NS2, monomeric p7 or 
oligomers, reproducibility of data becomes further complicated. Accordingly, more 
accurate experimental approaches need to be investigated or identified to better define the 
protein-protein interaction activities of p7, both viral and potentially cellular. 
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1.11 Project design and hypothesis 
The only functional study of p7 in vivo indicated that p7 is essential for successful 
intrahepatic infection in the chimpanzee model and illustrated its critical role in the viral 
life cycle [348]. Studies employing full-length HCVcc chimeras have indicated that p7 is 
also important in virus production and acts at a late stage during viral assembly and/or 
release [300,349,363]. It has also been shown that p7 interacts with NS2 and that this 
interaction is required for efficient viral assembly and release [65,172,306,355,357]. In 
addition, p7 was shown to impact cellular organelle pH and reduce the number of highly 
acidic vesicles more rapidly than ion channel defective p7 mutant sequences [178]. 
Recently, another group has shown that p7 is important for formation of completely 
assembled capsids and enveloped virions, as p7-defective HCV genomes showed 
different sedimentation profiles on density gradients and generated proteinase K sensitive 
virions; a possible indication of envelope deficiency [30].   However, it is still unknown 
at which step p7 acts during the HCV life cycle. The impact of p7 regulation of 
intracellular vesicles and interaction with NS2 on virus production remain important 
questions. The aim of this study was to further elucidate the role of p7 in the HCV life 
cycle. We hypothesized that p7 is involved in the HCV assembly process at a late stage 
after nucleocapsid formation. 
The first part of this project was to test the effect of p7 in infectious virus production 
using the HCVcc system.  A number of studies have already performed mutational 
analyses on p7 and reported the importance of this protein for infectious virus production 
both in vivo and in vitro using the chimpanzee model and HCVcc system, respectively  
[300,348,349,363]. However, these reports focused mostly on the two basic residues 
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within the cytoplasmic loop since it was shown to be important for in vitro ion channel 
activity and intracellular vesicle pH modulation. In our study, and for the first time, we 
have created a panel of triple alanine mutations covering most of TM1, the cytoplasmic 
loop and TM2 of p7 in order to pinpoint which domains and amino acids are important in 
p7 function. We believe that a more comprehensive mutational analysis might provide 
additional clues into p7 function. 
The adapted strain of JFH-1, termed JFH1D, was used for the majority of the 
experiments outlined in this work. The reason behind using the JFH1D strain in this report 
was because it replicates with high efficiency compared to wild-type JFH-1 [365]. Due to 
the high replication rate of JFH1D it would be less expected to acquire adaptive mutation 
during passage that could potentially confound the effect of our mutation of interest. 
However, to prevent even JFH1D from acquiring such confounding mutations, 
experiments addressing virus production and assembly were confirmed in S29 cells, 
which represent a single-cycle virus production assay. S29 cells are a sub-clone of Huh7 
that express significantly lower levels of CD81 (an HCV entry receptor), and therefore, 
permit RNA replication and virus production, but do not support entry. Using this system 
provides the ability to analyze infectious virus production without the confounding effect 
of multiple rounds of infection cycles, during which mutant reversion could happen [365]. 
The second part of this project was to investigate at which step of the viral life cycle 
p7 plays its role. There still exists a debate on the precise role of p7 in the HCV life cycle. 
However, multiple studies have shown that p7 acts at a late stage during viral assembly 
and/or release [300,349]. The observed interaction of p7 with the viral protein NS2 has 
been suggested to be required for efficient viral assembly and/or release 
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[65,172,355,357]. p7 was shown to reduce the number of intracellular acidic vesicles 
more than defective p7 mutants at the two basic residues of the cytoplasmic loop, 
emphasizing the importance of p7 role in protecting HCV particles from acidic 
inactivation [178]. Similarly, transfection of HCV genomes defective at the cytoplasmic 
loop of p7 was shown to generate proteinase-K sensitive virions, a possible indication of 
envelope deficiency [30]. In spite of this, the exact role of p7 is still unclear. How the 
previously identified interaction pattern of p7 with other viral proteins and the viroporin 
activity contributes to the whole HCV life cycle still remains to be elucidated. The aim of 
this part was to identify at which step of the virus life cycle p7 affects virus production. 
Detailed functional characterization of the effects of generated mutations at multiple 
stages of the HCV life cycle were performed, including polyprotein processing, core/LD 
association, core protein oligomerization and virus release. 
The last part of this study was aimed at performing forced evolution studies in which 
the mutants with defects in virus production were cultured for a prolonged period of time 
so that they would have the opportunity to acquire compensatory mutations that would 
correct for the effects of the originally-engineered mutations. Such compensatory 
mutations are key to providing clues as to which domains of other proteins might form 
critical interactions with p7. Forced evolution studies on HIV provided important 
information in respect to assembly and viral genome incorporation [366-368]. When this 
approach was performed in full-length and chimeric HCV genomes, it led to the 
generation of multiple adaptive strains of HCV that are currently used instead of the low 
replicating wild-type JFH-1 strain [365,369]. This strategy was also performed on 
genomes containing mutations in viral proteins other than p7 and provided information 
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regarding the interaction patterns of such proteins [359,363]. This is the first study to 
utilise this approach on HCV genomes harboring p7 mutations. The subsequent analysis 
we performed on one of the compensatory mutations we identified provides strong clues 
regarding p7 function. 
 
 
1.12 Research objectives 
i. To determine the effect of HCV p7 on production of infectious virus (chapter 
3). 
ii. To identify the most important domains/amino acids residues of p7 for virus 
propagation in cell culture (chapter 3 and 4). 
iii. To investigate at which step of the virus life cycle p7 plays its role (chapter 4). 
iv. To determine potential viral proteins that bind to p7 using the forced evolution 
analysis (chapter 5). 
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1 Cell culture 
Transfections and infections were performed in Huh-7.5 cells (generous gift from 
C.M. Rice, Rockefeller University/Apath Inc. LLC, USA [353]) and S29 cells (subclone 
of Huh-7 cells representing a single-cycle virus production assay [365], generous gift 
from S. Emerson, NIH, USA). Both cell lines were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM, Invitrogen/Life Technology) supplemented with 10% fetal calf 
serum and 1% penicillin/streptomycin, referred to as complete medium (CM). All cells 
were grown at 37ºC in 5% CO2. 
2.2 Cloning and plasmid construction 
Plasmids were constructed mainly in the backbone of JFH1D, which was itself derived 
from a cell culture-adapted JFH-1 strain (genotype 2a genome previously described, see 
section 2.11). Other adapted strains of JFH-1 backgrounds were also used and illustrated 
in Figure 2.1.  PCR mutagenesis was employed to introduce the desired mutations with 
primers that included the BsiWI and NotI restriction sites within the JFH1D backbone 
(primers listed in Table 2.1). The JFH1D plasmid and PCR products were digested with 
BsiW1 and Not1 (New England Biolabs) and fragments gel-purified then ligated using the 
Rapid DNA Ligation Kit (Roche). The ∆GDD negative control was created using the 
QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) and specific 
primers that omitted the GDD motif of NS5B. The same strategy was also employed to 
create other plasmid backgrounds including: (i) the JFH1A4S backbone was created by 
using a primer encoding the E1 A4 epitope in the backbone of JFH1S, which includes 
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only the NS2 adaptive mutation, and (ii) the JFH1D-FLAG background that was created by 
transferring the gene segment between BsiWI and AleI restriction sites from a FLAG-
modified JFH-AM2 that was a gift from T. Wang (University of Pittsburgh, USA) [370].  
Selected p7 mutations were then recreated by substituting the BsiWI and AleI digested 
fragment from the original p7 mutant plasmids into JFH1A4S and JFH1D-FLAG. All plasmid 
sequences were verified by enzymatic digestion and double-stranded DNA sequencing. 
2.3 In vitro transcription and RNA transfection 
Mutant and control plasmids were linearized by XbaI digestion for 2 h at 37ºC and 1 
μg of each linearized plasmid was used for in vitro RNA transcription using the T7 
Megascript kit (Ambion). RNA integrity was verified by gel electrophoresis. RNA 
transcripts were transfected using DMRIE-C reagent (Invitrogen/Life Technology) into 
1x106 Huh-7.5 or S29 cells plated in 10 cm cell culture dishes 24 h prior to transfection. 
We preferred to use DMRIE-C over electroporation because it provides comparable 
transfection efficiencies, but more importantly, it shows no cytotoxicity effects and 
transfection can be done easily in case of adherent cells such as those used in this project 
(Huh7.5 and S29).   
2.4 Antibodies  
The following antibodies were used in this study: mouse anti-HCV core monoclonal 
antibody (mAb) (B2; Anogen) was used for both indirect IF at a dilution of 1:200 and 
Western blot (WB) analysis at a dilution of 1:1000; mouse anti-NS3 mAb at a dilution of 
1:5000 (C65371M; Meridian Life Science); mouse mAb A4 (anti-E1; a kind gift from 
Harry Greenberg, Stanford university, USA); mouse anti-NS2 (6H6, a kind gift from 
Charles M. Rice, Rockefeller university, USA) both used for WB analysis at dilutions of 
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1:2000; mouse anti-E2 (AP33; generous gift from Genentech) used at a dilution of 
1:1000; mouse anti-GAPDH mAb at a dilution of 1:10000 (Abcam); sheep anti-NS5A 
antiserum (a kind gift from Mark Harris, University of Leeds, UK) used for WB analysis 
at dilutions of 1:10000. HCV core in gradient analyses was detected using mouse anti-
core mAb (MA1-080; Pierce Research) at a dilution of 1:1000, and mouse anti-ADRP 
(Progen Biotechnik) was used at a dilution of 1:1000. Alexa Flour® 488 anti-mouse 
secondary antibody (Invitrogen/Life Technology) was used for indirect IF at a dilution of 
1:1000. Goat anti-mouse and donkey anti-sheep horseradish peroxidase (HRP)-labelled 
secondary antibodies (Santa Cruz Biotechnology) were used for WB analysis at a dilution 
of 1:1000.  
2.5 Indirect IF  
Cells were grown on 8-well chamber slides (Thermo Scientific), fixed in 100% 
acetone for 2 min, washed with phosphate buffer saline (PBS) pH 7.4 and incubated with 
primary antibody for 20 min. Then, slides were washed 3 times with PBS and incubated 
with the secondary antibody for an additional 20 min and washed 3 times with PBS. 
Slides were then mounted with Vectashield Hard Set mounting medium containing DAPI 
(Vector Laboratories). 
2.6 Virus titration  
Virus titres were determined by endpoint dilution assay for focus-forming units (ffu) 
as described previously [325]. Briefly, 8-well chamber slides were seeded with 4x105 
Huh-7.5 cells per well 24 h prior to infection. At 72 h post-transfection, cell supernatants 
were clarified through Millex-HV 45 μm filters (Millipore) before being serially diluted 
10-fold with complete DMEM. 100 μl of each dilution was inoculated for 4 h before 
 
 
61 
 
being removed and replaced with complete DMEM. At 72 h post-infection cells were 
fixed with acetone and core protein was visualized by indirect IF. Virus titres were 
expressed as the number of ffu per ml of supernatant, where a focus was defined by a 
cluster of 3 or more infected cells. 
2.7 Titration of intracellular infectious virus 
At 72 h post-transfection, cells were trypsinized, pelleted by centrifugation at 400 x g 
and re-suspended in 1 ml of CM. The re-suspended cells were then lysed by 4 cycles of 
freeze/thaw (3 min freeze/ 3 min thaw) in a dry ice/methanol bath and pelleted by 
centrifugation at 1500 x g. Virus titres were determined as described above. 
2.8 SDS-PAGE and WB analysis 
At indicated time-points post-transfection, cells were trypsinized, pelleted by 
centrifugation at 400 x g and re-suspended in 300 μl of passive lysis buffer (Promega). 
Cellular debris was pelleted by centrifugation after 30 min incubation on ice. A fraction 
of the cell lysates was then loaded in a 1:1 ratio with 2X loading dye for SDS-PAGE. To 
visualize extracellular core protein, at 72 h post-transfection 12 ml of transfection 
supernatant (pooled from 2x10 cm dishes) was passed through a 0.45 μm filter and 
subjected to ultracentrifugation at 80,000 x g for 4 h at 4ºC using a Sorvall TH-614 rotor. 
Pellets were re-suspended in 20 μl of 2 X loading dye and the full amount was subjected 
to SDS-PAGE and WB. All WBs performed in this study were exposed and analyzed 
using the luminescent image analyzer (Image Quant LAS 4000, GE Santé Bio-Sciences).      
2.9 Confocal microscopy 
At 72 h post-transfection, cells were seeded onto 8-well chamber slides and 48 h later 
washed with PBS and fixed with 4% paraformaldehyde for 20 min, then washed and 
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permeabilized with 0.1 % Triton X-100 for 15 min. Following this, cells were washed and 
incubated with anti-core Ab at a 1:200 dilution in 5% BSA/PBS. Next, cells were washed 
3 times and incubated with anti-mouse labelled with Alexa Fluor® 488. To visualize LD 
the HCS LipidTOX Deep Red neutral lipid stain (Invitrogen/Life Technology) was added 
to Vectashield Hard Set mounting medium containing DAPI (Vector Laboratories) at a 
1:200 dilution then added to the slides and examined by laser scanning confocal 
microscopy. 
2.10 Iodixanol density gradient fractionation 
Two 10 cm plates per construct were transfected as described above and cells were 
trypsinized 72 h post-transfection, pelleted by centrifugation and re-suspended in 0.5 ml 
of lysis buffer (50 mM Tris (pH 7.5), 140 mM NaCl, 5 mM EDTA and 0.5% Triton-
X100) and incubated for 30 min on ice then cleared by centrifugation. The clarified 0.5 
ml were loaded over 4.5 ml of pre-formed 10-50% iodixanol gradients (prepared using 
OptiPrep Density Gradient Medium (Sigma) and Hank`s balanced salt solution 
(Invitrogen/Life Technology). Samples were then ultracentrifuged at 100,000 x g for 16 h 
at 4ºC using a Beckman SW55Ti rotor. Next, ten fractions (0.5 ml/fraction) for each 
construct were collected from the top of each tube. 50 µl from each fraction was retained 
before the protein precipitation process for measurement of density of each fraction using 
a refractometer (Fisher Scientific). Proteins were extracted from the remainder of each 
fraction by methanol precipitation at -20ºC for 40 min, and then pelleted by 
centrifugation. The resultant pellets were re-suspended in 50 μl of 2 X loading buffer, 
boiled and then probed for core protein by WB analysis. 
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The same exact procedure was also performed by re-suspending the pellet from two 
plates for each mutant and control with 0.5 ml CM and subjecting them to multiple cycles 
of freeze/thaw instead of using the above mentioned lysis buffer to compare core 
sedimentation profiles using two different lysis methods (freeze/thaw vs. chemical lysis 
with detergent). 
2.11 Bafilomycin A1 and ammonium chloride treatments 
4 pM Bafilomycin A1 (dissolved in DMSO) and 12 mM NH4Cl were prepared and 
used to treat Huh-7.5 or S29 cells that had received mutant or control RNA 48 h 
previously. These concentrations were chosen after testing a range of 1–50 pM 
(Bafilomycin A1) and 6–50 mM (ammonium chloride (NH4Cl)). Supernatants from 
harvested cells were used for titer determination or WB as outlined previously. 
2.12 Forced evolution assay 
For each control and mutant, cells were washed and trypsinized 72 h post-transfection 
and re-suspended in 10 ml CM. 2 ml of suspension were then combined with 7 ml CM. 
200 µl of suspension combined with 200 µl CM for each mutant and control were seeded 
on 8-well chamber slides and incubated for 48 h at 37°C to assess viral spread as an initial 
indication of virus adaptation. The same procedure was repeated for up to 10 rounds or 
until a significant increase was observed in core staining on the chamber slide after each 
round. Cells were also monitored daily for any visual cell death and in such a case, the 
passaging was terminated. A fraction of clarified supernatants from each mutant was 
saved from each round and used to confirm virus adaptation using the infection titration 
assay. 
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2.13 Reverse transcription, PCR amplification and sequencing of rescued mutants 
To identify compensatory mutations that had arisen during passage of the mutant(s), 
supernatant from the passage of interest plate was first used for 2 rounds of infection to 
increase the rescued virus population. RNA was extracted from supernatants using 
TRIzolLS (Invitrogen). Reverse transcription was performed to generate cDNA from the 
adaptive mutants. Multiple PCR reactions using primers designed to cover the whole 
HCV genome were then performed, as previously described [365,371]. Sequencing of the 
PCR products was performed at the Centre for Applied Genomics at the Hospital for Sick 
Children (Toronto, Canada). 
2.14 Flow cytometric analysis of intracellular core protein 
S29 cells transfected with the mutants or controls were collected after trypsinization 
and washed 4 times with PBS. Cells pellets were then prepared for staining using FIX & 
PERM® Cell Fixation and Permeabilization Kits (Invirogen) following manufacturer’s 
instruction. After being washed with PBS, cells were incubated with antibody to HCV 
core (1:400 dilution) for 30 min followed by 3 washes and incubation with FITC-labeled 
secondary antibody at a 1:1000 dilution for 30 min, then washed 3 times. Pellets were 
resuspended in 500 μl PBS and analyzed by flow cytometry. 
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Figure 2.1 Illustrative diagram of the different strains of JFH-1 used in this 
study. The adaptive mutations indicated by the stars are as follow: the E2 adaptive 
mutation is N417S and the NS2 adaptive mutation is Q1012R. FLAG and A4 epitope 
locations are also indicated. The strain names are shown on the right side of the panel. 
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Table 2.1 Primers used to generate p7 mutations 
List of the primers used to generate p7 mutations. Bold letters represent the changes 
introduced on the indicated backgrounds to introduce the desired mutations. Where the 
reverse primer is not provided means the reverse complement sequence of the forward 
primer was used as reverse primer. 
*Same primers were used to accommodate N765D in the backgrounds of p7 mutations 
from p7(3) to p7(13) using their respective background created previously. 
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CHAPTER 3: RESULTS (EFFECT OF p7 ON INFECTIOUS VIRUS 
PRODUCTION) 
 
Results in this chapter along with those in chapter 4 have been published in Virus 
Research, 2013; 176(1-2):199-210. 
3.1 Generation of p7 mutations 
Previous reports have identified adaptive and compensatory mutations within p7 that 
enhanced virus production [363,365,372-374]. The cytoplasmic loop region contains 
highly conserved basic residues, K33 and R35, known to impact infectivity in 
chimpanzees, as well as in vitro ion channel activity and virus production in cell culture 
[300,303,348,349]. Based on these findings we hypothesized that a comprehensive 
mutational analysis of TM1 and the cytoplasmic loop might provide additional insight 
into the function of this protein. Accordingly, seven alanine triplet mutations (termed 
p7(1) to p7(7)) were generated to cover the TM1, TM2 and cytoplasmic loop of p7 
(Figure 3.1). These mutations were constructed in the background of a full-length, cell 
culture-adapted strain of HCV JFH-1 termed JFH1D, which contains adaptive mutations 
in E2 (N417S) and NS2 (Q1012R) that function cooperatively to increase infectious virus 
production [365]. 
3.2 Effect of p7 mutations within TM1 and the cytoplasmic loop on infectious virus 
production using single-cycle assay 
To test the effects of the generated mutations on infectious virus production, we used 
a single-cycle virus production assay. Here, the mutant RNA genomes were transfected 
into S29 cells, which express very low levels of CD81, the major receptor for HCV entry 
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[365]. These cells permit RNA replication and virus particle production, yet do not 
support virus entry, allowing a comparison between mutants and their ability to generate 
infectious progeny without the confounding effects associated with multiple infectious 
cycles. Core, NS3 and NS5A WB analyses performed on transfected S29 cell lysates at 
72 h post-transfection showed similar band intensities among the mutants when compared 
with JFH1D. This indicated that transfection efficiencies were comparable and protein 
expression/processing was not affected by the mutations generated in p7 (Figure 3.2A). 
These comparable protein levels also exclude possible effects on RNA replication or 
genome instability that may have been caused by the generated mutations. The negative 
control (∆GDD) contained a deletion within the active site of the HCV NS5B polymerase 
and, therefore, produced no core, NS3 or NS5A proteins. 
At 72 h post-transfection, S29 cells were trypsinized and re-plated in 8-well chamber 
slides. Two days later, indirect IF analysis confirmed that all mutant genomes and the 
JFH1D control possessed relatively similar HCV core staining patterns, with 
approximately 25% of cells being positive for core protein (Figure 3.2B). Cells 
transfected with ∆GDD displayed no core-positive cells. 
Next, to quantify the effects of the generated mutations on virus production, we 
measured the levels of infectious virus present in the supernatants of transfected cells 
(Figure 3.2C). Mutations p7(1) (located at the N-terminal end of TM1) and p7(4) (located 
near the C-terminal end), as well as mutations p7(6) and p7(7) (within the cytoplasmic 
loop) reduced infectious virus production to levels lower than the detection limit of the 
assay. In contrast, p7(2) and p7(3), located in the central region of TM1, decreased virus 
production by ~2 logs. The mutation near the carboxy-terminal end of TM1 (p7(5)) 
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showed little effect on virus production, which was likely due to the conservative amino 
acid changes comprising this mutation (VAA-AVV). Taken together, these data indicated 
that TM1 and the cytoplasmic loop of p7 are important for production of infectious virus, 
and that the amino acids located within the central region of TM1 are seemingly less 
critical for p7 function. 
3.3 Effect of TM1 and the cytoplasmic loop mutations on infectious virus production 
using Huh-7.5 cells 
To verify the single cycle assay findings, we repeated the above experiments in Huh-
7.5 cells and found that the levels of core, NS3 and NS5A proteins on WBs were 
apparently different among the mutant viruses (Figure 3.3A). Core IF staining patterns 
were also different from that observed in S29 cells (Figure 3.3B), demonstrating that 
mutations p7(1), p7(4), p7(6) and p7(7) substantially affected virus spread. Mutant virus 
p7(5) exhibited similar core staining to that of JFH1D with >90% of the cells positive for 
core. The ∆GDD control displayed no core signal. Virus production at 72 h post-
transfection of Huh-7.5 (Figure 3.3C) was higher than that from S29 cells (Figure 3.3C), 
but overall patterns between mutants were similar (minor differences between cell lines 
for p7(1) and p7(6) were disregarded since they fell under the assay cut-off). The 
observed differences on protein levels, core staining patterns and virus titers correlated 
with the effects of virus spread and are, therefore, due to the amplification and 
accumulation of virus that occurs in the permissive Huh-7.5 cells, which is in agreement 
with previous findings [359]. These results indicated that the generated mutant genomes 
are indeed defective in infectious virus production. 
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Figure 3.1 Construction of p7 mutants. 13 alanine triplet mutants were constructed 
in the background of JFH1D, which exhibits enhanced infectious virus production 
compared to JFH-1 due to the presence of adaptive mutations in E2 (N417S) and NS2 
(Q1012R), (indicated by *). The p7 TM1, TM2 and the cytoplasmic loop with the amino 
acid compositions are shown, with mutated residues, and affected polyprotein amino 
acids numbers are shown in the table. Valine was introduced at positions where the 
original amino acid was alanine. The lower diagram indicates the locations of the p7 
mutants on the membrane topology of p7. 
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Figure 3.2 Single cycle virus production assay analysis of p7 mutant viruses. (A) 
S29 cells transfected with the p7 mutants or controls (JFH1D and ∆GDD) were lysed and 
probed with antibodies recognizing core, NS3, NS5A and GAPDH by WB analysis. (B) 
S29 cells were transfected with equivalent amounts of transcribed RNA representing p7 
mutants and controls (JFH1D and ∆GDD). At 72 h post-transfection, cells were seeded 
onto 8-well chamber slides and two days later washed, fixed and stained for core (green) 
and DAPI (blue). Scale bars represent 50 µm. (C) Culture supernatants were filtered and 
serially diluted to infect naïve Huh-7.5 cells. At three days post-infection, virus titers 
were determined by limiting dilution focus-forming assay. Focus-forming assays were 
performed in triplicate and error bars represent standard error of the mean. The bold line 
represents the cut off of the assay, which was 10 ffu/ml. Results represent three 
independent transfection/infection experiments. 
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Figure 3.3 The p7 cytoplasmic loop and TM1 are important for virus production. 
(A) Huh-7.5 cells transfected with the p7 mutant panel and controls were lysed and 
probed with antibodies recognizing core, NS3, NS5A and GAPDH by WB. Results are 
representative of three independent experiments. (B) Huh-7.5 cells were transfected with 
equivalent amounts of transcribed RNA representing p7 mutants and controls (JFH1D and 
∆GDD). At 72 h post-transfection cells were seeded onto 8-well chamber slides and two 
days later washed, fixed and stained for core (green) and DAPI (blue). Scale bars 
represent 50 µm. (C) Culture supernatants were filtered and virus titers determined in 
Huh-7.5 cells. Titrations were performed in triplicate and error bars represent standard 
error of the mean. 
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3.4 Effect of TM2 mutations on infectious virus production using Huh-7.5 cells 
In this study a set of triple alanine changes covering TM2 was also constructed, 
attempting to expand our knowledge on the functionally essential portions of the p7 
protein. Huh-7.5 cells were transfected with the generated constructs and controls. 72 h 
later cells were trypsinized and subjected to WB analysis for core (Figure 3.4A). Levels 
of the core protein were different among mutants. The negative control ΔGDD produced 
no detectable level of core, as expected. The core protein levels correlated with the effects 
on virus spread (Figure 3.4B) after an IF staining of core protein on the constructs and 
control done at 72h post-transfection. Therefore, these results indicated that the generated 
mutants did not affect genome stability or polyprotein processing.  
Consequently, to quantify the effects of the generated mutations on infectious virus 
production, clarified supernatants from each mutation and control at 72 h post-
transfection were used to infect naïve Huh-7.5 cells followed by a ffu assay (Figure 
3.4C). We found that TM2 of p7 is also important for virus production in cell culture with 
a maximum effect appearing with p7(9 to 13) causing a decrease in titres to below 
detectable levels. While mutation p7(8), located at the C-terminus of TM2, showed a 
lesser defect on virus production than the rest of TM2 mutations, it maintained a 
significant reduction of approximately 2 log less than the control JFH1D. Taken together, 
these results suggest that all domains of p7 are critical for infectious virus production. We 
did not examine the expression of other viral proteins or confirm infectious virus 
production using the single-cycle assay for the TM2 mutations because these mutations 
were only to be further used in forced evolution assays (see chapter 5). 
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Figure 3.4 The p7 TM2 is important for virus production. (A) Huh-7.5 cells 
transfected with the p7 mutants (8-13) and controls were lysed and probed with 
antibodies recognizing core and GAPDH by WB. Results are representative of two 
independent experiments. (B) Huh-7.5 cells were transfected with equivalent amounts of 
transcribed RNA representing p7 mutants and controls (JFH1D and ∆GDD). At 72 h post-
transfection cells were seeded onto 8-well chamber slides and two days later washed, 
fixed and stained for core (green) and DAPI (blue), and visualized under 20 X 
magnification. (C) Culture supernatants were filtered and virus titers determined in Huh-
7.5 cells. Titrations were performed in triplicate and error bars represent standard error of 
the mean. 
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CHAPTER 4: RESULTS (ANALYSIS OF THE ROLE OF p7 IN THE HCV LIFE 
CYCLE) 
Results in this chapter along with those in chapter 3 have been published in Virus 
Research, 2013; 176(1-2):199-210. Only the mutations at TM1 and the cytoplasmic loop 
were analyzed in this section. 
4.1 Analysis of intracellular and extracellular species of virus particles 
The reduction of extracellular infectious virus exhibited by some of the p7 mutants 
could result from two possibilities: (i) p7 mutants exhibit wild-type levels of released 
virus particles, but these have reduced infectivity, or (ii) an overall reduction in the 
production of particles. To determine which of these possibilities occurred, supernatants 
from Huh-7.5 cells transfected with the mutants and controls were collected, clarified, 
layered over a 20% sucrose cushion and subjected to ultracentrifugation. Huh-7.5 cells 
were used in this case to maximize yields of virus. WB analysis was then performed on 
the pelleted material (Figure 4.1A). Core protein was detectable only for genomes that 
produced high levels of infectious particles (JFH1D and p7(5)), demonstrating that the 
mutations introduced into p7 decreased the production of core-containing particles, as 
opposed to reducing the infectivity of  secreted virions. The mutations p7(2) and p7(3) 
were shown to produce low levels of infectious virus, but particles could not be detected 
in the supernatant as this assay was not sensitive enough to detect such small amounts of 
virus production. 
From the results outlined above, we next investigated whether the p7 mutants that 
produced little or no extracellular infectivity were also compromised for intracellular 
infectivity. Accordingly, S29 cells transfected with p7 mutants and controls were 
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subjected to multiple freeze/thaw cycles to obtain intracellular infectious virus at 72 h 
post-transfection. In parallel, filtered supernatants were collected and viruses from both 
sources were used to inoculate naïve Huh-7.5 cells to measure infectious titers (Figure 
4.1B). All mutants with reduced extracellular titers also displayed similar reductions in 
the levels of intracellular infectious virus. Taken together, these results demonstrate that 
the mutations made within p7 resulted in an absence of core-containing HCV particles 
outside the cell, most likely resulting from their compromised ability to generate 
infectious particles in the intracellular environment. 
4.2 Mutations in p7 TM1 and the cytoplasmic loop do not affect core sedimentation 
profiles 
The above data indicated that the selected p7 mutations within TM1 and the 
cytoplasmic loop render HCV unable to produce intracellular infectious virions. 
However, it was unclear whether these mutants were assembling intracellular particles 
that were non-infectious, or were incapable of building the nucleocapsid structure.  
Typically, density gradient fractionation of transfected cell lysates has revealed that 
intracellular HCV core exists at various densities, presumably representing sequential 
stages of capsid assembly. These species are thought to include monomeric core 
associated with LD, and oligomerized core representing both newly forming 
nucleocapsids and virions associated with triglycerides and β-lipoprotein (VLDL and 
LDL) complexes [41,358,359,375]. Therefore, we sought to determine whether any of our 
p7 mutants displayed altered patterns of core distribution following centrifugation 
through density gradients. To do this, two mutations within TM1 (p7(2) and p7(4)) and 
one mutation within the cytoplasmic loop (p7(7)) were selected for gradient analysis 
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because they spanned the TM1 and cytoplasmic loop region of p7. Also, these mutants 
displayed a spectrum of effects on virus production; (p7(2)) showed a moderate 
reduction, whereas p7(4) and p7(7) produced no detectable infectious virus. These mutant 
RNA genomes were transfected into Huh-7.5 cells, and 72 h later, intracellular lysates 
were harvested using TNE buffer containing 0.5% Triton X-100. This mild detergent was 
chosen to preserve core-core oligomers within the lysate while disrupting core-membrane 
complexes that may otherwise be sufficiently dense to traverse into the gradient and be 
misinterpreted as multi-ordered structures. Lysates were then loaded over 10-50% 
iodixanol gradients and subjected to ultracentrifugation. Ten gradient fractions were 
collected from top (fraction 1) to bottom (fraction 10) and analysed by WB for core 
(Figure 4.2). In all constructs tested, varying core protein levels were observed in 
fractions 1-3, likely representing monomeric core species (densities ranging from 1.019 to 
1.090 g/cm3). The strongest core bands, which we propose represent naked viral 
nucleocapsids, typically appeared in fractions 6 and 7 with a density range of 1.145-1.169 
g/cm3. It is unlikely that these core structures were enveloped/complexed with 
membranes, since no infectivity was associated with these or any fractions. While slight 
variations were regularly observed in these assays, we did not observe any consistently 
noticeable differences between JFH1D and any of the p7 mutants tested with respect to 
core patterns on WB, except that JFH1D showed higher core band intensities in the blots 
due to its ability to spread and produce more infectious virus. However, using a lysis 
buffer containing a detergent capable of breaking core-core interactions (TNE + 0.5% 
SDS) resulted in a loss of core from fractions 6 and 7, with most of the protein now being 
found in the top fractions of the gradient (Figure 4.2). It should be noted that a 
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comparison of lysis methods (freeze-thaw vs. TNE+0.5% TX-100) on cells harbouring 
JFH1D revealed differences in core banding patterns, indicating that these distinct lysis 
methods influence the migration of liberated core through iodixanol gradients (Figure 
4.3). Similarly, spinning harvested intracellular particles through a sucrose cushion prior 
to their ultracentrifugation through an iodixanol gradient made little difference (with the 
exception of filtering out core in fractions 1-3) to those results obtained without a cushion 
(Figure 4.3). In comparison, we also observed no differences between p7 mutants and 
JFH1D in core and viral RNA sedimentation profile when lysates were prepared by 
freeze-thaw (Figure 4.4). Of further note is that RNA quantitation for core-containing 
gradient fractions was irrelevant, since gradients run on a negative control (ΔGDD) also 
gave a peak of RNA in these fractions (Figure 4.4). This final result suggests that 
gradient-derived RNA patterns obtained from intracellular lysates are complicated by the 
existence of input RNA delivered during the transfection process. Overall, the data 
obtained from density gradient experiments suggest that the p7 mutants tested here were 
competent for nucleocapsid assembly. 
4.4 p7 TM1 and the cytoplasmic loop do not affect core targeting to LD 
We next wished to determine whether p7 might influence the recruitment of core 
protein to LD, the proposed platform for virion formation [96]. Accordingly, Huh-7.5 
cells were transfected with the mutant genomes and stained for core protein and LD. As 
shown in Figure 4.5, no differences in core/LD association were observed between the 
JFH1D control and any of the p7 mutants studied in this chapter. These data conclusively 
demonstrate that neither p7 TM1 nor the cytoplasmic loop affect the targeting of core 
protein to LD. 
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Figure 4.1 Extracellular particle production and comparison of intracellular vs. 
extracellular infectious virus. (A) Huh-7.5 cells were transfected with equivalent 
amounts of transcribed RNA representing p7 mutants and controls (JFH1D and ∆GDD) 
for 72 h. 12 ml of supernatants (pooled from 2x10 cm dishes) representing p7 mutants 
and controls were loaded over 2 ml of 20% sucrose, ultracentrifuged and the pellet probed 
by WB for core protein. Results are representative of two independent 
transfection/infection experiments. (B) S29 cells were transfected as above and 72 h post-
transfection extracellular (solid bars) and intracellular (open bars) infectious virus 
production were measured by focus-forming assay in triplicate, and means plus standard 
errors are plotted. Results are representative of two independent transfection/infection 
experiments.  
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Figure 4.2 Iodixanol gradient analysis of p7 mutant viruses using lysis buffer 
with detergent. Huh-7.5 cells were transfected with RNA representing selected p7 
mutant viruses including TM1 mutants p7(2) and p7(4) as well as the cytoplasmic loop 
mutant p7(7), and JFH1D was used as a control. At 72 h post-transfection intracellular 
lysates were harvested, loaded over preformed 10-50% iodixanol gradients and subjected 
to ultracentrifugation. Ten fractions from each tube were collected from top (fraction 1) to 
bottom (fraction 10). Density measurements (g/cm3) on each fraction were measured 
using a refractometer (top panel), and WB analyses for core and ADRP (LD marker) were 
performed (middle and bottom panels). Results are representative of three independent 
transfection/infection experiments. 
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Figure 4.3 Comparison of iodixanol gradient separation of core species, for 
JFH1D using different conditions. Huh-7.5 cells were transfected with RNA encoding 
JFH1D. At 72 h post-transfection intracellular lysates were prepared by multiple 
freeze/thaw cycles (top panel), treated with TNE buffer containing 0.1% TX-100 (middle 
panel) or lysed with TNE containing TX-100 and sedimented through a 20% sucrose 
cushion (bottom panel). The resultant lysates were loaded over preformed 10–50% 
iodixanol gradients and subjected to ultracentrifugation. Ten fractions from each tube 
were collected from top (fraction 1) to bottom (fraction 10) and WB analyses for core 
were performed. Results are representative of three independent transfection experiments. 
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Figure 4.4 Iodixanol gradient analyses of p7 mutant viruses after lysis using 
freeze/thaw method. (A) Huh-7.5 cells were transfected with RNAs of the indicated p7 
mutants and controls. At 72 h post-transfection intracellular lysates were obtained by 
multiple freeze and thaw cycles and loaded over preformed 10-50% iodixanol gradients. 
Ten fractions from each tube were collected from top (fraction 1) to bottom (fraction 10) 
and Real-Time RT-PCR (dashed line), virus titre (solid line), and WB analyses for core 
and ADRP were performed. (B) Density measurements (g/cm3) on each fraction were 
measured using a refractometer. Results are representative of three independent 
transfection/infection experiments. 
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Figure 4.5 Analysis of core/LD association. Huh-7.5 cells were transfected with 
equivalent amounts of transcribed RNA representing p7 mutants and controls (JFH1D and 
∆GDD). At 72 h post-transfection, cells were seeded onto 8-well chamber slides and two 
days later washed and stained as described above. Cells were visualized by confocal 
microscopy under oil immersion. Scale bars represent 10 µm. Enlarged areas from the 
merged image are shown on the right. Blue represents DAPI-stained nuclei, green 
fluorescence represents HCV core protein, and red represents LD staining. Results are 
representative of three independent experiments. 
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4.5 Mutation of the p7 cytoplasmic loop results in a time-dependent reduction of E2 
levels  
It has previously been shown that p7 can regulate pH in intracellular compartments 
[178], presumably to protect the virus from acid-induced degradation during egress. 
However, p7 may have an additional, separate function that involves an interaction with 
NS2, and this interaction may be important for localization of p7 with other viral proteins, 
including core and E2, at the site of assembly [65,172,306,355,357]. Therefore, it became 
essential to test some of our p7 mutants for an effect on viral glycoproteins E1 and E2. To 
do this, we recreated the panel of p7 mutations in a version of JFH1D that contained a 
substituted FLAG tag sequence within E2, termed JFH1D-FLAG. The use of the FLAG tag 
was necessary because the N417S adaptive mutation in E2 contained within the JFH1D 
backbone is located within the epitope recognized by most antibodies that recognize JFH-
1 E2. To rule out the possibility that the FLAG sequence would cause confounding 
effects on virus production, we measured the amount of infectious virus produced from 
the FLAG-containing p7 mutant RNAs and observed a slight, but relatively insignificant, 
reduction in virus titre compared to that of without FLAG (Figure 4.6). Importantly 
however, the same pattern of effects on infectious virus production was observed for 
these mutants compared to their counterparts that lack the FLAG sequence. Upon 
transfection of S29 cells with these p7 mutants, WB analysis indicated that all mutants 
displayed similar levels of core protein (Figure 4.7A). However, this was not the case for 
E2, where some variation in E2 levels was observed among mutants, with the greatest 
reduction being apparent in p7(7) (cytoplasmic loop mutant containing the two conserved 
basic residues). These results were confirmed in Huh-7.5 cells (Figure 4.7B). 
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Figure 4.6 p7 mutants in the background of JFH1D-FLAG showed a similar 
pattern of virus infectivity as JFH1D virus. Huh-7.5 cells were transfected with 
equivalent amounts of RNA representing p7 mutants and controls (JFH1D, JFH1D-FLAG 
and ∆GDD). At 72 h post-transfection culture supernatants were clarified and virus titres 
determined. Assays were performed in triplicate and error bars represent standard error of 
the mean. Results are representative of two independent transfection/infection 
experiments. 
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Figure 4.7 Effects of p7 mutation on FLAG-E2 levels in S29 and Huh-7.5 cells. 
S29 (A) and Huh-7.5 (B) cells were transfected with p7 mutants generated in the 
background of JFH1D-FLAG along with controls (JFH1D-FLAG and ∆GDD). At 72 h post-
transfection intracellular lysates were obtained and probed with antibodies against E2, 
core, and GAPDH by WB analysis. 
 
 
 
 
B 
 
 
91 
 
To rule out the possibility that this effect on E2 was related to the presence of the 
FLAG sequence, we first created a new construct termed JFH1S that is the same as 
JFH1D, except that it lacks the N417S adaptive mutation in E2. This construct had to be 
used to allow detection of native E2 by antibodies that bind JFH-1 E2. In turn, JFH1S was 
then further modified by substituting a short sequence of E1 for the analogous sequence 
from HCV strain H77, to produce JFH1A4S. This strategy, reported elsewhere [66], 
renders E1 detectable by the E1 antibody A4. The modifications required to produce both 
these constructs did reduce virus production by approximately 15-fold (JFH1S) and 70-
fold (JFH1A4S) compared to JFH1D (Figure 4.8). However, the level of virus production 
remained sufficient for analysis.  
To examine effects on both E1 and E2, we first introduced selected p7 mutations (1, 3, 
4, 6 and 7) into the background of JFH1A4S. WB analysis indicated that all mutants 
displayed insignificant variations in core, NS2 and E1 protein levels (Figure 4.9). 
However, this was not the case for p7(7) (the loop mutant containing the two conserved 
basic residues), where a substantial reduction in E2 was apparent. These results were 
confirmed in S29 cells (Figure 4.9).  To analyze the reduction in E2 more quantitatively, 
the WB band intensities for E2 were measured by densitometry relative to that of core 
expressed from each mutant. Additionally, NS2 levels were measured in this manner 
(Figure 4.9). This analysis conclusively demonstrated that E2 levels expressed from p7(7) 
were notably lower compared to JFH1A4S and the other p7 mutants, whereas NS2 levels 
remained unchanged. These results suggest that modification of the dibasic residues 
within the p7 cytoplasmic loop leads to a reduction of E2 glycoprotein levels. 
 
 
 
92 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8 Comparison of virus production from JFH1D, JFH1S and JFH1A4S. 
Huh-7.5 cells were transfected with the indicated constructs. 72 h later, culture 
supernatants were filtered and virus titers determined. Titrations were performed in 
triplicate and error bars represent standard error of the mean. 
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Figure 4.9 Effects of p7 mutations on E2 levels. (A) Huh-7.5 and S29 cells were 
transfected with the indicated p7 mutants generated in the background of JFH1A4S along 
with appropriate controls (JFH1A4S and ∆GDD). At 72 h post-transfection, intracellular 
lysates were obtained and probed with antibodies against E1, E2, NS2, core, and GAPDH 
by WB. (B) Band intensity measurements for core and E2 where each mutant’s band 
intensity was calculated relative to JFH1A4S. 
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Previous reports have demonstrated that alteration of the p7 cytoplasmic loop can 
result in the detection of E2-p7-NS2 precursors by WB analysis [349]. While we did not 
observe this effect in Figure 4.7 or 4.9, E2 and NS2 blots were repeated using SDS-based 
Laemmli buffer in addition to our usual CHAPS-based buffer (Figure 4.10). Here, we also 
saw no evidence of precursors on either the E2 or NS2 protein blots. Therefore, we 
presume that the observed phenotype for p7(7) resulted from direct effects on the protein 
itself rather than a processing defect. To further investigate the observed reduction of E2 
in the p7(7) mutant, we carried out a time course analysis of E2 levels at 24, 48, and 72 h 
post-transfection in S29 cells. Since S29 cells are non-permissive for HCV entry, they 
represent a relatively synchronized state of viral protein production upon transfection, 
which is ideally suited for this experiment. Here, the JFH1S strain of virus was used since 
it produces higher viral titers than JFH1A4S and detection of E1 protein was not required 
for this experiment. p7(1) was also included as an additional control since, like p7(7), it 
produces no infectious virus, yet generates near wild-type levels of E2. Lysates were 
prepared from each time-point and E2, core, and GAPDH levels were probed by WB 
(Figure 4.11). It was observed that at 24 h post-transfection the mutants and controls 
produced barely detectable levels of both E2 and core. By contrast, at the 48 h time-point, 
only p7(1) and the JFH1SA4S control displayed comparable levels of core and E2, with a 
slightly reduced amount of E2 in the case of p7(7). However, E2 levels expressed from 
p7(7) were noticeably reduced by 72 h compared to what they were at 48 h, as well as 
being diminished compared to the other constructs tested. 
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Figure 4.10 Examination of HCV 
proteins under different lysis conditions. 
S29 were transfected with RNA encoding 
JFH1S, ΔGDD or p7(7). 72 h later, cells were 
lysed and probed with antibodies 
recognizing core, NS2, E2 and GAPDH by 
WB. Results are representative of three 
independent experiments. 
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Figure 4.11 Time course of E2, core, and GAPDH expression assessed by WB. 
Prepared lysates at 24, 48, and 72 h post-transfection of S29 cells for the mutants p7(1) 
and p7(7) generated in the background of JFH1S were collected and probed for the 
indicated viral proteins. Results are representative of two independent experiments. 
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In a previous report it was shown that expression of p7 or HCV infection prevents 
intracellular vesicle acidification, but this was not the case for the loop mutation [178]. 
This group also found that p7-induced loss of vesicle acidification contributes to 
infectious virus production as the p7 loop mutant genome transfection was partially 
rescued for infectious virus production after treating the cells with the acidification 
inhibitor bafilomycin A1.   We interpreted this to mean that the observed reduction in E2 
levels in the case of p7(7) was due to the loss of the ability of p7 to mediate the proper pH 
environment during the assembly process, resulting in E2 degradation. Therefore, we 
attempted to rescue both infectious virus production and E2 levels from p7(7) by treating 
transfected cells with (i) Bafilomycin A1, to inhibit vesicular acidification as performed 
previously [178], and (ii) ammonium chloride , a lysosomal inhibitor (Figure 4.12). 
However, we observed no restoration of virus production or E2 to levels seen with JFH1S. 
Taken together, these results indicated that the mutations present in p7(7) appear to result 
in lower levels of E2, which cannot be restored through the inhibition of lysosome or 
vesicular acidification (see discussion for further details).  
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Figure 4.12 Effect of Bafilomycin A1 and NH4Cl treatment on E2 levels. (A) Huh-
7.5 cells were transfected with equivalent amounts of RNA representing p7(7) or control 
constructs (JFH1D and ∆GDD). At 48 h post-transfection, media were removed and 
replaced with media containing (i) 4 pM Bafilomycin A1, (ii) 12 mM NH4Cl or (iii) 
DMSO only. 24 h later, culture supernatants were filtered and virus titers determined. 
Note that serial dilution was performed in media containing the treatment agents. 
Titrations were performed in triplicate and error bars represent standard error of the mean. 
(B) S29 cells treated as above (here, JFH1S was used as a positive control instead of 
JFH1D in order to permit detection of E2) were lysed and probed for core, E2 and 
GAPDH by WB. Results are representative of three independent experiments. 
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CHAPTER 5: RESULTS (FORCED EVOLUTION ANALYSIS OF p7 MUTANTS) 
 
Results in this chapter have been submitted for publication while Virology Journal. 
5.1 Passaging of p7 mutants led to adaptation and restoration of virus production   
by acquisition of amino acid changes on different viral proteins 
To further investigate the observed effect on infectious virus production of the p7 
mutants generated, we passaged transfected cells with the generated p7 mutations 1-13 
for multiple rounds in order to allow virus production-defective mutants to gain one or 
more compensatory mutations, which would provide genetic evidence for a possible p7 
protein binding partner, or shed light on the amino acids playing the greatest role in p7 
function. This strategy is illustrated in Figure 5.1 and has been employed by other groups 
[359,365]. Firstly, the viral spread on Huh-7.5 cells transfected with RNA of the 
respective mutants after each round lasting for 72 h was monitored. Upon confirmation of 
viral adaptation through indirect IF and observation of increased viral spread, passaging 
was terminated see Figure 5.1. 
Mutation p7(1) showed a significant increase in viral spread at day 12 (R4) post-
transfection. Efficient viral spread for the mutants p7(2) and p7(3) was observed at day 15 
(R5) post-transfection. Mutant p7(6) completely regained efficient viral spread  at day 30 
(R10) post-transfection. Mutants p7(8) and p7(10) displayed efficient viral spread at day 
18 (R6) and day 21 (R7) post-transfection, respectively. The mutations p7(4), p7(7), 
p7(9), p7(11), p7(12) and p7(13) were unable to restore virus production and passaging 
was terminated at the end of round 10 (Figure 5.2). 
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The mutants that showed a significant increase in virus spread were selected for 
determination of the consensus sequence of the polyprotein to identify the changes 
responsible for restoring viral kinetics. To do this, RNAs isolated from respective mutants 
were amplified by RT-PCR and sequenced, as described in Materials and Methods. The 
mutations we found are listed in Table 5.1. 
5.2 The adaptive mutation N765D is important for p7 function 
One of the compensatory mutations we found was the N765D that significantly 
restored viral spread of p7(1) mutations. Aspartic acid was acquired at position 765 where 
the original amino acid in JFH1D or JFH-1 is asparagine; the alanine residues changed 
downstream remained unmodified throughout the passaging, indicating the importance of 
this amino acid for p7 function. The N765D mutation was reported before as an adaptive 
mutation that increases virus production by itself or combined with other mutations in E2 
and NS2 [365]. In another report, N765D was found to restore virus production after a 
defect caused by exchange of the NS2 helix in the second TMD (trans membrane domain) 
of JFH-1 by that of the Con1 strain [65]. Therefore, we decided to further investigate the 
role of the N765D mutation in infectious virus production. Subsequent analyses of other 
mutations identified will be conducted by a future student.     
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Figure 5.1 A schematic representation of the method used to identify 
compensatory mutations. Huh-7.5 cells were transfected with RNAs encoding p7 
mutant viruses. Cells were passaged each round for 72 h, and supernatants from the day 
of passage were saved to determine infectious titers. For R1 to R10, the cells themselves 
were passaged, and checked for viral spread by core IF as a 1st indicator of adaptation. 
Once improved virus spread was observed, supernatants were passaged for P1 and P2 to 
enrich for rescued virus. For P1, naive Huh-7.5 cells were infected using supernatants 
from the last round in which significant virus spread was observed. Seventy-two hours 
later, supernatants were removed and used to infect naive cells for a second passage (P2). 
RNA was harvested from P2 supernatants 72 h post-infection and used for sequencing. 
(Figure modified from [359]) 
        
Cells Sups Sups Cells 
Cells 
R1 R2 Up to 
R10 
R3 P2 P1 
Transfect 
RNA 
RNA Extracted 
from supernatants 
and sequenced 
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Figure 5.2 p7 mutant passaging. IF core staining of p7 mutant passaging where each 
round lasted 72 h. Trypsinized cells after each round were resuspended in CM, seeded in 
8-well chamber slides, and incubated for further 48 h. Slides were then stained for core 
(green) and nuclei (blue). Slides were examined using a fluorescent microscope at 20 X 
magnification. 
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  Table 5.1 Sequence analysis of the rescued p7 mutants 
 
RNAs were extracted from the virus stocks generated after long-term passage of the 
indicated p7 mutants (1st column), followed by cDNA synthesis, and full genome 
amplification and sequencing was performed. The resultant changes including nucleotides 
(nt), amino acids (aa) and locations are shown in the 2nd, 3rd, and 4th columns, 
respectively. The time at which each virus mutant showed a significant change in virus 
spread is indicated by round number and days post-transfection in the last column. 
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Firstly, we reintroduced N765D in the background of its cognate plasmid (p7(1)) or in 
the background of JFH1D to confirm if this adaptive mutation is responsible for the 
observed rescue of viral spread after passaging. We found that N765D significantly 
increased virus production and was the responsible mutation in the rescue of the triple 
alanine mutant at the p7(1) position (Figure 5.3). There were additional mutations found 
in the p7(1) rescued virus, but we did not further analyse these because it was clear that 
N765D was responsible for the restoration, and the silent nature of the remaining 
substitutions omitted them from analysis. 
Next, we asked whether N765D was also sufficient for the other p7 mutations but 
could not be acquired through passaging because the virus might have been too weak to 
sustain itself in culture long enough to pick up rescue mutations. Accordingly, we 
recreated all p7 mutations (1 to 13) in the background of the maximal adapted strain of 
JFH-1 termed JFH1T, which has the two adaptive mutations previously described in 
JFH1D as well as the N765D. 72 h post-transfection of this panel of virus mutants, 
supernatants were collected and used to infect naïve Huh-7.5 cells in order to determine 
the effects on virus titer. We observed that N765D also restored virus production when 
introduced in the background of p7(3) and p7(8) genomes, but had no effect on the rest of 
the p7 mutations (Figure 5.4). This mutation was unfavorable for p7(2) and to a lesser 
extent for p7(5) as it reduced infectious virus production to undetectable levels compared 
with p7(2) and by one log compared with p7(5) in the background of JGH1D. These 
results indicated that N765D on p7 TM1 was able to restore alanine triplet changes at 
positions 765-767 (p7(1)), 771-773 (p7(3)) and 788-790 (p7(8)). 
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Figure 5.3 Effect of the N765D adaptive mutation on infectious virus production. 
Huh-7.5 cells were transfected with the indicated constructs. 72 h later, culture 
supernatants were filtered and virus titers determined. Titrations were performed in 
triplicate and error bars represent standard error of the mean. 
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Figure 5.4 Effect of the N765D adaptive mutation on infectious virus production 
for all of the generated p7 mutants. Huh-7.5 cells were transfected with the indicated 
constructs. 72 h later, culture supernatants were filtered and virus titers determined. 
Titrations were performed in triplicate and error bars represent standard error of the mean. 
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5.3 Additional analysis of N765D revealed a key role of p7 in efficient viral assembly 
and provided evidence against involvement in HCV entry processes. 
 In a previous report N765D by itself increased infectious virus production 2 logs 
more than that of wild-type JFH-1, and when combined with the E2 and NS2 adaptive 
mutations, it increased virus production to 3 to 4 logs higher than wild-type [365]. 
Therefore, we took advantage of the ability of the N765D mutation to enhance virus 
production when combined with other adaptive mutations in order to further analyse the 
role of p7. Our hypothesis was that whatever p7 is doing, it can do it better in the 
presence of the N765D mutation. To test this hypothesis, we tested the effects of the 
presence and absence of N765D on the accumulation of virus particles in culture 
supernatants at 72 h post-transfection. In this case, we selected JFH1T (containing E2, p7 
and NS2 adaptive mutations), JFH1D (containing only E2 and NS2 adaptive mutations), 
JFH1N765D (containing only the p7 N765D adaptive mutation) and wild type JFH-1 
(Figure 5.5). We compared the levels of virus particles produced by these constructs in 
the culture supernatant after particle sedimentation through 20% sucrose cushion. Here, 
we also took advantage of the single-cycle virus production assay to allow for a 
comparison between mutants in a system that does not include virus entry steps. 
However, for results in this experiment to be valid, we needed to be sure that we had 
similar transfection efficiencies among constructs used. Therefore, we evaluated 
intracellular core protein expression by WB and flow cytometry analysis to ensure that all 
constructs used were comparable in transfection efficiencies (Figure 5.6). 
Virus titration assays were then performed on all transfections and we confirmed that 
all constructs were competent for infectious virus production. As expected, we observed 
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1-2 log differences in virus production with JFH1T > JFH1D > JFH1N765D > wild type 
JFH-1. Culture supernatants were then also loaded at the top of a 20% sucrose cushion, 
which allows only assembled particles to pass through after short duration, but high 
velocity ultracentrifugation. WB analysis for core protein performed on pelleted virus 
demonstrated that extracellular HCV accumulation in JFH1T was more than that of JFH1D 
(Figure 5.7), and the only difference between these two constructs is the presence of the 
p7 adaptive mutation, N765D. Similarly, JFH1N765D accumulated more HCV particles 
than wild type JFH-1 with the difference between them also being the presence of the p7 
N765D mutation. Taken together these results indicated that the N765D mutation in p7 
enhanced the production of virus particles from transfected cells in an entry-null system. 
The interpretation of these findings, with some extrapolation, could be that if N765D 
enhances the function of p7, and that effect was observed in the increased production of 
virus in an entry-null system, then p7 likely is involved in the later stages of virus 
production, and not in the virus entry process.  
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Figure 5.5 Illustrative diagram for the constructs selected to analyze N765D 
adaptive mutation effect on extracellular HCV particles secretions. Constructs names 
are shown at the right. The adaptive mutations E2 (N417S), p7 (N765D), and NS2 
(Q1012R) are indicated by an asterisk on their respective genes. 
 
 
 
 
 
 
 
 
 
 
 
111 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6 Analysis of transfection efficiencies by WB and flow cytometry. S29 
cells were transfected with each construct indicated and 27 h later cells were pelleted, 
lysed and probed for intracellular core and GAPDH (A). Band intensity measurements for 
each sample from two independent transfection experiments were performed (B). Cell 
lysates were also stained for core protein and analyzed for percentages of core protein 
contents by flow cytometry (C). 
 
C  
 
 
112 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 5.7 N765D increased the production of extracellular HCV particles. (A) 72 
h post-transfection S29 cell supernatants were clarified and used for infection titer 
measurements by ffu assay (B) or loaded over preformed 20% sucrose cushions, 
ultracentrifuged and the pellet probed for core protein by WB. Repeats of 4 independent 
experiments are shown. 
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CHAPTER 6: DISCUSSION 
 
The functionality of the p7 protein is one of the more poorly understood aspects of the 
HCV life cycle. p7 is important for both successful HCV infection in chimpanzees as well 
as virus production in cell culture, yet is seemingly dispensable for virus entry and RNA 
replication [300,301,306,321,348,349]. Multiple studies indicate that p7 forms ion 
channels in artificial membranes, leading to its inclusion in the viroporin protein family 
[308,316,318]. Notably, amino acids required for the ion channel activity of p7 were also 
shown to be important for pH modulation of intracellular vesicles in cell culture, and this 
activity was important for maintaining infectious virus production [178]. In this study, for 
the 1st time, we performed an extensive mutational analysis to determine at which stage of 
the viral life cycle p7 acts. Alanine triplet mutations spanning most of TM1, the 
cytoplasmic loop, and TM2 were generated and tested for their ability to produce virus, 
and subsequently, some of these mutations were tested at different stages of the viral life 
cycle. The data indicated that regions of TM1, the cytoplasmic loop and TM2 of p7 are 
important for virus production. p7 was not involved in virus release as reductions in both 
intra- and extracellular infectious virus were observed. Furthermore, mutating TM1 and 
the cytoplasmic loop of p7 did not alter core localization to LD, and capsid assembly was 
seemingly unaffected. Most importantly, we observed that alanine substitution of the two 
basic residues within the cytoplasmic loop of p7 caused a reduction in the amount of E2 
present in transfected cells. Furthermore, we performed forced evolution analysis of p7 
mutants by passaging of virus production incompetent mutants and provided more 
information on the most important amino acid composition of the p7 protein. We found 
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that the amino acid at position 765 is uniquely important for p7 function. Further analysis 
of the N765D substitution highlighted the importance of p7 in the HCV assembly process. 
The 1st mutants analyzed in this study covered the TM1 domain of p7 were found to 
be critical for virus production, but to a lesser extent of the amino acids situated in the 
central region of TM1. This observation suggests that the positioning of the N- and C-
termini of TM1 might be critical for anchoring the membrane-spanning region into the 
ER, and that mutation of this sequence may disrupt this positioning, thereby inhibiting 
virus production. Mutation of amino acids located near the N-terminal end of TM1 
(p7(1)) caused complete abrogation of virus production. This result is in agreement with a 
study showing that the H17 residue (H767 in the polyprotein of JFH-1) within TM1 is 
important for virus production and is part of a HXXXW-like motif found in the influenza 
virus M2 protein, which is the main functional element of the M2 channels [321]. 
However, a separate study generated a single alanine substitution at residue N17 (N767 in 
the polyprotein of J6) in the context of the J6/JFH-1 chimeric virus and found an 
insignificant effect on virus production [300]. These discrepancies might be explained by 
the chimeric nature of the viral backbone used in the latter study, or may result from the 
triple alanine mutation studied here more effectively disrupting the M2-like motif. 
Interestingly, it has been previously reported that an adaptive mutation in this region 
(N15D; N765D in the JFH-1 polyprotein) enhanced virus production by 10-fold itself, 
further demonstrating the importance of these residues and suggesting that a putative 
interaction with other viral proteins is mediated by residues contained within the region 
mutated in p7(1) [365]. Mutations p7(2) and p7(3) lie within the central region of TM1 
and reduced virus production to approximately 50% of the levels observed with JFH1D. 
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The alanines substituted in this region replace uncharged hydrophobic amino acids 
(GLLYFA) and we propose, therefore, that these substitutions likely alter the optimal 
structure of this segment, but not sufficiently enough to terminate virion production. 
Others have also found this region to have a minimal effect on virus production [300]. 
The p7(4) mutation completely abrogated virus production, indicating the importance of 
one or more amino acids in this region. Interestingly, others identified a compensatory 
mutation (F26L; also mutated in our p7(4) construct) that rescued a mutation in the core 
protein [364], indicating that p7 and core may work together through a direct interaction 
that has yet to be demonstrated. Thus, the targeted p7(4) residues might disrupt such an 
interaction. These results highlight that the integrity of both the N- and C-terminal regions 
of TM1 are important for the generation of infectious virus. It should also be noted that, 
as is usually the case for alanine-scanning mutagenic analyses, some of the constructed 
mutations were more conservative than others. For example, it was unsurprising that 
p7(5) (mutation from VAA to AAV) exhibited no reduction in virus production, most 
likely since the overall folding of p7 was largely unaltered due to the conservative 
changes being introduced. This would not be the case for some of the other mutants 
discussed later where more drastic mutations were made, including p7(6) (mutation from 
WHI to AAA) and p7(7) (mutation from RGR to AAA). In the case of these latter 
mutants, we cannot exclude that virus production is abrogated due to p7 structural 
deformities resulting from the non-conservative amino acid changes. 
The data herein also showed that the two basic residues of the cytoplasmic loop of p7, 
R33 and R35, were important for infectious virus production. The importance of the 
cytoplasmic loop in virus production was shown previously in multiple studies employing 
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the HCVcc system, and in vivo after intrahepatic injection of chimpanzees [300,348,349]. 
Most of these studies concentrated on the two basic residues (R33 and R35), since it was 
previously shown that these residues were important for p7 ion channel activity in 
artificial membrane assays [308,316]. In this study we performed a comprehensive, side-
by-side comparison of viruses containing mutations covering most of the loop sequence. 
We observed that the p7(7) mutant, which included the dibasic residues discussed above, 
and mutation p7(6), which is situated at the junction of the cytoplasmic loop, both 
terminated virus production. Moreover, a previous study created a W30F mutation, within 
the region that was also mutated in our p7(6), and found to be an important residue for p7 
function and virus production [349]. Therefore, we have confirmed the importance of the 
cytoplasmic loop structure in virus production. 
Similarly, we also showed that TM2 of p7 is important for virus production in cell 
culture. In agreement with a previous report showing that a mutation in p7 TM2 (Y42F) 
(included in p7(9) in our study) reduced infectious virus production and release [349]. On 
the other hand, St. Gelais et al. showed that amino acid residues that might affect ion 
channel activity or drug resistance in p7, including the mutations G39A (J4 sequence) 
(included in p7(8)) and P49A (included in p7(9)), cause a specific ion channel formation 
defect. This group also indicated that Pro 49 may serve to regulate efficient 
oligomerization of p7 channel complexes. Furthermore, in the same report, a L(50-55)A 
mutation (included in p7(12) and p7(13)) did not affect ion channel oligomerization but 
showed differential sensitivity to the ion channel blockers amantadine and rimantadine, 
highlighting the importance of this region of p7 in ion channel structure and drug 
sensitivity [320]. So, our study was the first comprehensive study showing the importance 
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of TM2 in infectious virus production. It was noticeable that TM2 mutations showed 
more drastic effects on virus production compared to TM1 mutations. One possible 
explanation for these differences are that TM2 may be more important for p7 structure 
and function. This also could be explained by the nature of amino acid changes that we 
introduced, i.e., the alanine changes had less impact on TM1 membrane integration but 
disrupted TM2 insertion through the ER membrane.     
In order to identify at which stage of the viral life cycle p7 play its role, we tested only 
the mutations at TM1 and the cytoplasmic loop at multiple steps of the virus life cycle. 
During the early stages of virus assembly, core protein traffics to the surface of LDs, 
which are proposed to serve as a platform for virion formation [96]. Thus, we have tested 
our mutation at this stage and conclusively demonstrated that none of the p7 mutants 
tested affected core protein accumulation around LD. One recent study proposed that the 
core/LD association results from inefficient virus assembly and that efficiently 
assembling virus strain Jc1 did not accumulate significant levels of core/LD association. 
[355]. However, this was not the case in our study as the efficiently-assembling JFH1D, as 
well as all virus production-defective mutants, showed equivalent core/LD association. 
Another report employed the less efficient LD core accumulating strain Jc1. They found 
that mutations in the p7 cytoplasmic loop affected the unloading of core protein from 
LDs, resulting in a retention of core around LDs after quantitation of core on isolated 
cellular LDs by flotation through a discontinuous density gradient [30]. It was also found 
through partial and full gene swaps that compatibilities between p7 and the first NS2 
trans-membrane domains were required to induce core-ER localization [355]. 
Correspondingly, other studies visualized that p7 can manipulate the intracellular 
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distribution of NS2 and disrupt its binding pattern with other viral proteins [172]. 
Moreover, a study tracking core protein in live cells found that the movements of 
cytoplasmic labelled-core puncta were dependent on NS2 function [170]. Ultimately, a 
p7-NS2 interaction with the NS3-4A complex was shown to be important for viral protein 
colocalization patterns and was suggested to perform the unloading process of core 
protein from LD into sites of virus assembly [174]. To sum up, p7 could be an important 
secondary factor for unloading of core protein from LD toward further assembly 
processes where NS2 protein is the major player, but it requires assistance through a p7 
interaction. 
The molecular details of HCV assembly are currently under intense investigation and 
are a matter of much debate. Following the recruitment of core to LDs, HCV capsid 
presumably begins to assemble through oligomerization of core, forming virus particles 
associated with a copy of the viral genome. This step presumably involves the production 
of multiple structures including oligomerized core representing both newly-forming 
nucleocapsids, and end-stage nucleocapsids associated with triglycerides and β-
lipoprotein (VLDL and LDL). Evidence for this model is supported by the observed 
pattern of core distribution within density gradient analyses [41,358,359,375]. In order to 
determine whether p7 plays a direct role in nucleocapsid assembly, we performed 
iodixanol gradient analyses on a select panel of p7 mutant viruses from cells that were 
lysed with a detergent-containing buffer. Based on the data shown, we can conclude with 
reasonable confidence that p7 does not affect core assembly because we were able to 
detect dense species of core protein in fractions 6-8 of the gradient. Our findings are in 
agreement with another group who performed similar gradient fractionation experiments 
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[376]. However, one study performed quantitation of core protein in the prepared 
fractions and found an increase in the proportion of incompletely assembled capsids 
indicating defective and delayed formation of intracellular core structures [30]. In fact, in 
this report it is not clear whether the accumulation of unassembled core containing 
fractions were due to impaired p7 effects on nucleocapsid assembly or if it is an effect 
due to impaired virus production in general, as p7 mutant genomes and controls showed 
comparable core concentrations in the fractions that were suggested to contain assembled 
core species. Also, the density measurements observed in the gradient fraction that 
contained the infectious particles were significantly higher (1.35 g/ml) than what is 
reported in the literature, with HCVcc particle densities ranging between 1.0 to 1.18 g/ml 
[41-45]. However, different protocols were employed, i.e., sucrose-based rate zonal 
centrifugation, whereas we used iodixanol equilibrium gradients. It would be interesting 
to determine whether we can identify nucleocapsid assembly defects in our mutants by 
rate zonal centrifugation.  In the end, the available data to date indicate that p7 is likely 
not involved in formation of multi-order structures of core during nucleocapsid assembly.  
Finally, Wozniak et al. found that p7 modulates intracellular proton conductance and 
increases lysosomal pH from 4.5 to 6.0 during HCV infection in cell culture [178]. This 
report also demonstrated that the acidification inhibitor Bafilomycin A1 and expression of 
influenza virus M2 protein restored virus production from a HCV genome mutated at the 
basic residues of the p7 cytoplasmic loop. Presumably, such a function would be 
important in protecting newly-formed virions from premature degradation at a late stage 
in virion production, specifically the envelope glycoproteins. We now show that a 
mutation within the loop that includes the same two basic residues also affected E2 
 
 
120 
 
protein expression and/or stability. Bafilomycin A1 and ammonium chloride did not 
restore virus production in our case. The Bafilomycin A1 rescue demonstrated in the 
previous report was partial and the mutation generated was a double alanine change of the 
two p7 basic residues. In addition, the replication foci were noticeably smaller in cells 
inoculated with the rescued mutant virus and the treatments were unable to rescue the 
delta p7 genome [178]. Therefore, in our case we suggested that the triple alanine changes 
at p7(7)  possibly caused a complete abrogation of p7 ion channel activity to an extent 
that could not be rescued by the above mentioned treatments. However, it is still unclear 
why this effect on E2 was only observed in the context of the cytoplasmic loop mutation 
(p7 (7)). One theory is that p7 plays a dual role in the late viral assembly process; on one 
hand p7 could mediate proper targeting of viral glycoproteins to the assembly site in 
collaboration with NS2, and we suggested that in case of the mutations p7(1-6) envelope 
protein is still retained in a protective environment that did not move to a site of further 
assembly due to the disruption of p7-NS2 interaction. On the other hand, p7 then could 
protect immature glycoproteins from degradation where envelope protein starts to be 
exposed to an unfavorable environment through an ion channel-like activity during late 
assembly or release. This theory is supported by a study showing that pseudoreversion in 
p7 within TM1 of p7 (N15D) combined with a mutation at NS2 (G25R) restored virus 
infectivity and colocalization of NS2 around LDs along with E2 and NS3 [65]. These 
effects were not a consequence of p7 ion channel function [356]. Also, Ma et al. showed 
that p7 deletion and mutations within the cytoplasmic loop affected the intracellular 
distribution of NS2 and E2 [172]. Similarly, Staplford et al. found that NS2 interaction 
with other viral proteins was dependent on p7 coexpression [66]. Furthermore, Vieyres et 
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al. recently constructed a functional HCV genome with a HA-tagged p7 and found that p7 
interacted with NS2 and colocalized with E2 on the ER membrane [306]. Therefore, it 
seems that p7 function may play two roles in HCV life cycle where it is required for NS2 
function in coordinating viral protein trafficking during the assembly process, while in the 
second role, it protects virion glycoprotein E2 from immature degradation through an ion 
channel-like activity disrupted by the p7(7) mutation studied herein. It is worth 
mentioning here that the HCV envelope proteins acquire high mannose and complex N-
linked glycans through post-translational modification, which usually occurs in the Golgi 
apparatus [176]. Also, envelope proteins rearrange the disulphide bonds necessary to 
prime HCV particles for low-pH mediated fusion, similar to pestivirus egress through the 
Golgi [131,176,177]. The trafficking of HCV particles and pre-envelope maturation is 
thought to happen within intracellular vesicles. At this stage, the viral protein p7 ion 
channel activity might be required to protect viral envelope proteins during passaging 
through Golgi. 
After passaging of p7 mutants by forced evolution assays, we found that one of the 
previously-identified adaptive mutations (N765D) amazingly also emerged as a 
compensatory mutation for some of our loss-of-function mutants and was able to restore 
alanine triplet changes on positions 765-767 (p7(1)), 771-773 (p7(3)) and 788-790 
(p7(8)). This indicates the importance of this residue in p7 structure and function. The 
N765D mutation was reported before as an adaptive mutation that increases virus 
production by itself or in combination with other adaptive mutations in E2 and NS2 
[365]. In another report, N765D was found to restore virus production after a defect 
caused by exchange of a NS2 helix in the second TMD (trans membrane domain) of JFH-
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1 by that of the Con1 strain [65]. Therefore, it seems this mutation is not only critical for 
p7 structure but also important for interaction engagements with other viral proteins such 
as NS2. We believe that the N-terminal end of p7 interacts with the second 
transmembrane domain of NS2.  The further analysis we performed on the adaptive 
mutation N765D indicated its importance for efficient accumulation of HCV particles in 
the culture supernatants. This indicates that p7 might act at the assembly stage and/or 
release but less likely at the entry process as these data were obtained in the entry-null 
S29 cell single-cycle assay. This finding is supported by multiple reports showing that 
HCV pseudo-particle entry occurs independent of p7 [350,351] and, later by indirect 
evidence, showing that the specific infectivity of p7 mutants was not reduced compared to 
wild-type virus [349]. Also, another study created an infectious construct containing a 
double HA-tagged p7 and found that p7 was not contained within the virion, which it 
would presumably be if it were required for entry, even in concentrated, affinity-purified 
or Flag-tagged preparations of virus [306]. Unexpectedly, introducing N765D in the 
background of HCV genome containing the mutation p(2) was not favorable and led to 
complete reduction of infectious virus, which could indicate that the functionality of 
certain amino acids may be influenced by its adjacent residues. However, it would be of 
significant interest to determine whether p7 structural features and ion channel activity 
are preserved in the presence of the alanine substitutions that were rescued by the N765D 
mutation, which would provide indirect evidence for the potential ion channel function. 
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Figure 6.1 Proposed model of p7 functions. Illustrative diagram of p7 function 
integrated into the HCV assembly process. The newly synthesized genome is delivered by 
NS4A to the site of nucleocapsid formation and NS3-4A supports genome packaging. 
Concurrently, the E1-E2 complex with ER-derived membrane makes up the viral 
envelope. The p7-NS2 complex orchestrates the recruitment of viral proteins to the site of 
assembly. Also, p7 forms an ion channel that mediate proper pH of virion-containing 
vesicles in order to protect immature virions until complete envelope glycoprotein 
maturation has taken place in the Golgi. 
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Conclusion:   
p7 is required for in vivo infectivity, and important for infectious virus production in 
cell culture. For unknown reasons, the cleavage of p7 from adjacent viral proteins is 
delayed, leading to the presence of precursor polypeptides (E2-p7, p7-NS2 or E2-p7-
NS2) proposed to have regulatory roles in virus production. Recent structural and 
topological studies have confirmed that p7 mainly localizes to the ER and contains two 
trans-membrane domains connected by a short cytoplasmic loop. By oligomerizing in the 
membrane, p7 is believed to form an ion channel that facilitates proton permeabilization 
in order to equilibrate intracellular vesicle pH to promote infectious virus production. The 
ion-channel activity can be inhibited by several compounds, with BIT225 and iminosugar 
derivatives showing the most promising results. Moreover, p7 interacts with NS2 and 
supports a late step in viral assembly and envelopment. The interaction pattern of p7 with 
other viral and host factors, and its exact contribution to infectious virus production 
remains poorly defined. 
In our study we confirmed, in a comprehensive mutational study that p7 is an 
important factor in virus production, specifically at a late stage in viral assembly, and it 
might be that p7 is a dual function protein. In one aspect, p7, presumably in its 
monomeric form, assists NS2 in gathering newly-formed capsids at LDs and glycoprotein 
complexes on the ER lumen for proper envelopment. Whereas, in its oligomeric state, p7 
protects glycoproteins from immature degradation during trafficking and release through 
an ion channel-like activity. A proposed model of p7 function in the HCV assembly 
process is shown in the Figure 6.1. 
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Future directions: 
To continue this work, we are interested to further analyze the generated p7 
mutations’ effects on various stages of the HCV life cycle, particularly at the assembly 
and release steps. Initially, we would like to test the p7 mutants’ sedimentation profiles by 
rate zonal centrifugation using sucrose gradients to be able to confirm whether p7 is 
involved in the formation of multi-order structures, such as HCV nucleocapsids. By doing 
this, we will have a clear image on the best way to perform gradient fractionations on 
HCV core protein. 
We are also interested in creating single alanine mutation exchanges of the two basic 
residues of the cytoplasmic loop and determine whether bafilomycin A1, NH4Cl, or p7 
expression in trans can rescue virus production. We also plan to perform time course 
analyses for E2 levels with pulse-chase assays. Doing such experiments will give us an 
idea if neutralization of intracellular vesicles contributes to infectious virus production 
and support our notion that p7 mediates E2 protection from premature degradation during 
HCV morphogenesis. 
  It’s very important to study the interaction pattern of p7 with other viral proteins. 
However, the small size of p7 and its membrane topology makes it a poorly immunogenic 
protein and, therefore, it is difficult to generate a reliable antibody against it. The idea of 
adding tag sequences to such a small protein might interfere with the actual binding 
pattern or the membrane topology of p7. It is possible that peptide antibody against p7 
could be generated using the carrier protein Keyhole limpet hemocyanin (KLH). Using 
this approach, synthetic peptides of only the accessible parts of p7 (the N- and C-termini 
and the cytoplasmic loop) would be the best choices to be conjugated with KLH. In 
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addition, studying the effect of p7 mutations on different viral protein localization and 
distribution by IF, particularly NS2 and E2 proteins, would be the best choice to gain 
more insight into the effect of p7 on other viral proteins, and would shed more light on 
the specific role of p7.  
Other adaptive mutations were also found to rescue viral spread in Huh-7.5 cells 
(mutations p7(2), p7(3), p7(6), p7(8), p7(10)) (see Table 5.1). Analysis of the identified 
mutations in the manner we used for the N765D will also provide important information 
on the most important residues of the p7 sequence and how certain viral proteins might 
have contributed to the rescue of the p7 defects. The N765D mutation was able to rescue 
alanine triplet changes at positions 765-767 (p7(1)), 771-773 (p7(3)) and 788-790 (p7(8)). 
We think it would be important to test whether these triple alanine mutants harboring 
N765D also preserve ion channel activity in artificial membrane assays. In this way, we 
could confirm the existence of the putative ion channel activity of p7. 
Looking a little deeper, it was reported that ion channel proteins of the non-enveloped 
viruses (togaviruses and lentiviruses) and the enveloped viruses (coronaviruses) mediate 
changes of host membrane potentials and promote viral budding at the plasma membrane 
or at an intracellular vesicle membrane in a process called depolarization-dependent 
exocytosis [310]. Coronaviruses are enveloped viruses with positive sense RNA genomes 
that also encode a viroporin, termed E protein. This viroporin was shown to mediate 
membrane rearrangements and formation of electron dense membrane structures derived 
from ER-Golgi intermediate compartments (ERGIC) and was suggested to play a role in 
scission of particles at the ERGIC [313]. It has never been considered whether p7 might 
mediate E protein-like activity. It would be exciting to test whether expression of p7 
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mediates the same membrane effects and modification of membrane potential. It would 
also be interesting to determine whether trafficking and release of HCV particles relies on 
ESCRT or COPII pathways or if p7 protein mediates this process. 
We firmly believe that p7 represents an attractive target for novel HCV treatment 
due to its small size and its importance for HCV infection. A better understanding of its 
function is of the utmost importance for development of a comprehensive therapeutic 
regimen. 
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